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BREAST CANCER
S1 - ROLE OF PATHOLOGIST IN MODERN ONCOLOGICAL TREATMENT
SNJEŽANA TOMIĆ1
1 University Hospital Split, Clinical Department for Pathology, Forensic Medicine and Cytology, Split, Croatia
The role of pathologists in cancer care is evolving to bring pathologists to the center of multidisci-
plinary collaborations, providing vital information to tumor boards about a patient’s cancer diagnosis and 
treatment options. Developments in diagnostic technology and the rise of precision medicine mean pathol-
ogists are more involved in clinical decisions than ever.
More than ever before, pathologists are increasingly involved in the clinical management of patients.
Unlike in the past, diagnosis of tumors is made prior to their removal, owing to the new ability to 
acquire small tissue through modern imaging-guided technologies; this means that clinicians and pathol-
ogists alike have all the salient information up-front and can make more complex management decisions.
Range of tests which can be undertaken by pathologists on these very small samples has expanded. 
It includes the use of histochemical stains, immunohistochemical markers and molecular markers. This 
allows much more accurate prognostication and prediction of response to treatment than before. One of 
the best examples is the situation for patients presenting with advanced lung cancer: most patients can 
now have a small sample of tumor taken despite their frailty, which can allow foremost an accurate diag-
nosis of the type of tumor present, but also to assess the suitability of the patient for various available 
targeted therapies (EGFR mutation, ALK or ROS translocation, PD-L1 expression). The entire assessment 
can now be completed within a week and available for early discussion at tumor board meetings – a vital 
requirement for these very ill patients. Pathologists nowadays must integrate multiple different pieces of 
information derived from various tests, and correlate these with clinical information; thus, pathologists 
must now take an active role in clinical decision-making.
Information provided by pathological assessment is far more detailed and clinically guided than 
before. The information provided by pathologists is dynamically adapted based on the point of the 
patient’s management and what is required at a given time in the patient’s journey: the information which 
must be provided on a biopsy is different from that needed from a surgical specimen, which is in turn dif-
ferent from that needed on a biopsy of recurrent disease.
The first hurdle which pathologists must overcome is to become familiar with, and to be able to inte-
grate the information derived from, the plethora of new and sophisticated techniques available which 
contribute to the depth of information accompanying the pathological diagnosis, including extensive 
sequencing and digital pathology. In achieving this, pathology departments must be more multidisci-
plinary than before: teams must consist both of medically-trained pathologists and of scientists from vari-
ous backgrounds, including molecular biologist, geneticists and bioinformaticians.
The challenge is to ensure that those new technologies are nonetheless regarded as being complemen-
tary techniques to classical pathology, and are not considered a replacement on the basis of expertise in a 
single technology. Ultimately, it is the morphological diagnosis which has the biggest impact on predict-
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ing prognosis and response to treatment in cancer, and technologies such as wider sequencing refine this. 
In the same vein, it remains absolutely necessary that the integration of data from all these sources be by 
a medically-trained pathologist, and translated into its clinical relevance, before being discussed with the 
clinical team at the tumor board meeting.
In general, pathologists will spend increasing amounts of time on each case in the future, and there 
will be a need for increasing specialization of individual pathologists. It is likely that, as the amount of 
information coming from increasingly large numbers of sources continues to increase, pathologists will be 
spending more and more time on each case, integrating this into a complete, clinically relevant report. 
Much of this will require the use of algorithmic analysis of the data to determine the best course of action 
for each individual patient. Developments in digital pathology will also allow more accurate and repro-
ducible assessment of quantitative data.
Pathologists – equipped with both their pathological and clinical backgrounds – will have an increas-
ingly important role to play in patient care, as long as laboratories remain well-resourced with both equip-
ment and with staff.
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S2 - THE CURRENT APROACH IN NEOADJUVANT SYSTEMIC TREATMENT 
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About twenty years ago the neoadjuvant systemic treatment (NST) has become the golden standard 
and widely accepted therapy for the breast cancer patients with operable, early breast cancer.
It can downstage tumors allowing breast-conserving surgery, rather than mastectomy with results in 
long term outcomes that are comparable with adjuvant therapy. In addition to its impact on surgery, the 
neoadjuvant setting offers a valuable opportunity to monitor individual tumor response and, in the future, 
enable personalized treatment, enhance development of the new drugs and targeted therapy. The assess-
ment of therapy response in neoadjuvant setting offers a relatively quick detection of patient subpopula-
tions that benefit from an intervention and the main, central principle of the neoadjuvant studies is that the 
response to the NST is a surrogate of the long - term outcome of the treatment and the disease.
In the NST achieving the pathologic complete response (pCR) is associated with favorable disease-
free and OS in early stage breast cancer. The correlation between pathologic response and long-term out-
comes is strongest for patients with triple negative breast cancer and HER2 positive, and less for hormone 
-positive and lower grade disease. The presence and extent of residual invasive cancer after standard 
neoadjuvant therapy is a strong prognostic factor for risk of recurrence. In patients with residual cancer 
burden (RCB), NST permits evaluation of the effectiveness of systemic therapy, which can be used to 
guide and adjust adjuvant treatment recommendations (according to subtype), and identify patients who 
are candidates for clinical trials of novel agents in adjuvant setting.
Future neoadjuvant studies will evaluate the value of new biomarkers to define the patients with high 
risk breast cancer that do not achieve pCR or those who despite reaching pCR develop disease recurrence. 
Analysis of gene expression changes in patient-matched sequential samples collected before and on treat-
ment logistically is more feasible and may be a promising way to consider the molecular changes that 
occur during treatment that are required for response. So, evolving technologies like NGS and gene expres-
sion profiles will improve our knowledge regarding the biology of the residual disease, the mechanisms 
behind treatment resistance, and potentially metastases.
Selection of the patients for NST is clear for patients with T4 tumors (locally advanced, inoperable 
disease including those with inflammatory breast cancer) and N2 or N3 regional nodal axillary disease. In 
patients with operable breast cancer who are clear candidates for adjuvant chemotherapy, NST may be 
considered if a patient desires breast-conserving surgery that is not possible due to breast-tumor size ratio, 
in patients with positive axillary nodes regardless of tumor size in the breast and in IHC aggressive sub-
types (triple negative, HER2 positive and highly proliferative luminal B tumors) if tumors are larger than 
2 cm independently of axillary status.
The decision on NST should be based on the predicted sensitivity to particular treatment types and 
predicted the benefit from their use. It usually incorporates chemotherapy, for HER2 positive disease in 
combination with anti-HER2 therapy and endocrine therapy for hormone-positive tumors.
The current approach is that the patients are managed by the coordinated multidisciplinary teams to 
decide the most appropriate neoadjuvant treatment plan and better stratify patients as well as the deter-
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mination of eligibility for enrollment into clinical trials that incorporate novel therapeutics or predictive 
biomarkers.
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Adjuvant systemic therapy is delivered after surgical treatment. It depends on individual risk of 
relapse and predicted sensitivity to treatment as well as benefit and toxicity of the therapy, comorbidity 
and collaboration between the health care team and patient.
The strongest prognostic factors in early breast cancer are expression of estrogene and progesterone 
receptor (ER/PR), HER2 and proliferation index, number of involved regional lymph nodes, tumor histol-
ogy, size, grade and presence of peritumoral vascular invasion. Those parameters integrated into different 
scoring systems allow relatively accurate estimation of the probability of recurrence and death from breast 
cancer. Accordingly, clinicians can objectively estimate outcome with local treatment only and benefit 
expected from systemic adjuvant therapy.
Adjuvant systemic therapy should start optimally within 3–6 weeks after surgery. Significant decrease 
in systemic therapy efficacy occurs when it is administered more than 12 weeks after surgery.
ER/PR and HER2 are the only validated predictive factors allowing the selection of patients for endo-
crine therapies (ETs) and anti-HER2 therapy. High ER expression is usually associated with lesser absolute 
benefit of chemotherapy.
ET should be used in all luminal-like cancers. Indication for chemotherapy in this subgroup depends 
on individual risk of relapse considering tumor burden and characteristics of aggressiveness (high grade, 
high proliferation, positive vascular invasion) as well as sensitivity to ET and patient preferences. ET con-
siders use of tamoxifen or aromatase inhibitor with or without ovarian function suppression depending 
on menopausal status and should last 5-10 years.
Few gene profiling tests which serve as decision making tools (Oncotype DX, MammaPrint, Prosigna, 
Endopredict) can be used to gain additional prognostic and predictive information of adjuvant chemo-
therapy benefit only in ER positive early breast cancer. They can help determine the individual’s recur-
rence risk and predict benefit of chemotherapy in general.
The most of luminal A cancers do not require chemotherapy, except those with high disease burden.
Characteristics associated with lower endocrine sensitivity include low ER expression, lack of PR 
expression, high tumor grade and high proliferation.
Sensitivity to chemotherapy depends on intrinsic subtype, the highest is for HER2 positive (in com-
bination with anti-HER2 therapy) and triple negative breast cancer (TNBC). Chemotherapy is recom-
mended for the TNBC, HER2 positive high-risk luminal-like HER2 negative tumors. Standard adjuvant 
chemotherapy is based on antracycline and taxane except for lower-risk patients. Non-antracycline regi-
mens are reserved for patients at risk for cardiac complications. Dose-dense protocols should be consid-
ered for highly proliferative tumors.
Adjuvant trastuzumab should be given for a year to all HER2-positive early breast cancer as it is 
highly effective and halves the recurrence and mortality risk. Dual blockade (trastuzumab/pertuzumab) 
can be considered in high risk patients. In cases of residual disease after neoadjuvant therapy, adjuvant 
trastuzumab can be replaces by adjuvant T-DM1. Neratinib can be considered in selected high risk patients 
nit previously treated with dual blockade.
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The final decision on adjuvant therapy should incorporate predictive treatment sequelae, patient’s 
biological age, general health status, comorbidities and preferences.
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Hormone receptor (HR) positive breast cancer (BC), early and metastatic, is the most common sub-
type (up to 70% of the cases). Endocrine therapy (ET) is the mainstay of treatment of this type of BC in 
adjuvant and metastatic settings. ET alone is an effective option even in the presence of visceral metastases 
unless there is an extensive symptomatic visceral involvement or proof of endocrine resistance. ET con-
sists of either: selective estrogen receptor modulator (SERM) (tamoxifen), selective estrogen receptor down 
regulator (SERD) (fulvestrant), aromatase inhibitors (AIs) (anastrozole, letrozole and exemestane) and 
progestin (megestrol acetate). Oophorectomy or administration of luteinizing hormone-releasing hor-
mone (LHRH) agonists in combination with one of the above mention ET drugs is recommended for pre-
menopausal women. Despite the fact that ET is the most effective treatment for HR+ mBC, vast majority of 
these patients will develop disease progression due to de novo or acquired ET resistance. Until recently, the 
only systemic treatment option for ET refractory disease was chemotherapy with its limitations regarding 
efficacy (less effectiveness than in ER- tumors) and toxicity. In order to overcome or delay the ET resis-
tance, plenty of preclinical and clinical researches have been done. As a result, there are two main treat-
ment options in the current clinical practice: inhibition of the mammalian target of rapamycin/PIK3CA 
(mTOR/PIK3CA) pathway by specific inhibitors (everolimus and alpelisib) and intervening in the cell 
cycle progression by targeting cyclin-dependent kinase 4/6 (CDK4/6). Three CDK4/6 inhibitors have been 
approved in metastatic HR +/HER2 - BC: palbociclib, ribociclib, and abemaciclib as first-line treatments in 
association with AIs (PALOMA-2, MONALEESA-2, and MONARCH-3) or as 2nd line therapies associated 
with fulvestrant (PALOMA-3, MONALEESA-3, and MONARCH-2). One trial addressed only pre-meno-
pausal patients who received goserelin, and AI or tamoxifen combined with ribociclib obtained the same 
magnitude of benefit (MONALEESA-7). Introduction CDK4/6 inhibitors with AIs in the 1st line treatment 
resulted in a progression-free survival (PFS) gain of about 10 months, a consistent significant hazard ratio 
(HR) ranging between 0.55 and 0.57, and an improvement in overall response rate (ORR). Quality of life is 
maintained over all of the 1st -line trials and the side effects consisting mainly of hematological toxicity 
which are easily manageable. CDK4/6 inhibitors showed positive results beyond 1st -line settings when 
associated with fulvestrant: there was a consistent PFS gain of about 5 to 7 months and a consistent sig-
nificant HR ranging from 0.50 to 0.55. Moreover, the first data concerning the overall survival (OS) were 
reported in the PALOMA-3 and MONALEESA trial. Nevertheless, there are some differences in the safety 
profile among the three CDK4/6 inhibitors: abemaciclib was associated with less grade 3 or 4 neutropenia 
(21% in the MONARCH-3 trial compared with 66% and 59% in the PALOMA-2 and MONALEESA-2 tri-
als, respectively), more grade 3 or 4 diarrhea (9.5% in the MONARCH-3 trial compared with 1.4% and 
1.2% in the PALOMA-2 and MONALEESA-2 trials, respectively) and with thromboembolic events (4% of 
patients). With ribociclib, a risk of QTc prolongation and liver toxicity has been reported. Abemaciclib 
showed promising single-agent activity, and possibly an activity against brain metastases knowing its 
ability to cross the blood-brain barrier.
Another potential mechanism of resistance to ET is the activation of the PI3K-AKT-mTOR pathway 
conducting to cell survival. In the pivotal BOLERO-2 phase III trial, it was demonstrated that everolimus 
(mTOR inhibitor) with exemestane prolonged the PFS and increased the ORR as compared with exemes-
tane alone after progression on AIs: gain in PFS of about 4 months (HR:0.43, 95% CI(0.35-0.54); p<0.001). 
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Another drug, alpelisib, an alpha-selective PI3K pathway inhibitor, in combination with fulvestrant in 
PI3K-mutated luminal mBC tested in SOLAR 1 trial shown significant PFS gain (mPFS 5.7 vs 11 months, 
HR:0.65, p<0.00065). SANDPIPER trial shown that combination of fulvestrant and taselisib prolongs mPFS 
from 5.7 to 7.4 months (HR:0.70, p=0.0037).
Despite the significant improvement in luminal metastatic BC treatment and treatment algorithm 
defined by current guidelines, many challenges remain. Most of the trials did not include pre-menopausal 
women, but most of the consensuses recommend the same treatment as for post-menopausal women with 
ovarian suppression or ablation. Another issue is treatment of very young women (chemotherapy vs 
ET+CDK4/6) and older or fragile patients with (ET alone or combination with CDK4/6 or PI3KCA inhibi-
tor). Does any patient with bone only disease required combined treatment or ET could be enough?
The correct sequencing of ET and targeted treatment association is still an unanswered issue. For 
instance, the mTOR inhibitor trials did not include patients pre-treated with CDK4/6 inhibitors and vice 
versa. Would the response to mTOR inhibitors be the same as it was before the era of CDK4/6 inhibitors? 
We still don’t know is there any benefit on potential continuation of CDK4/6 inhibition beyond progres-
sion in advanced ER +HER2 – BC. Another hypothesis is testing in several ongoing trials: the combination 
of CDK4/6 inhibitors with different PI3K/mTOR inhibitors.
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Breast cancer is heterogeneous disease, and HER2 positive breast cancers were initially connected with 
poor outcome. Anti-HER2 treatment substantially improved survival in early, as well as in advanced dis-
ease. Addition of trastuzumab to standard chemotherapy, the first anti-HER2 therapy, revolutionized 
breast cancer treatment and dramatically improved prognosis. Pertuzumab is another monoclonal anti-
body that binds to a different domain of HER2 receptor and prevents dimerisation of HER receptors, espe-
cially HER2/HER3.Its addition to taxane and trastuzumab in first-line therapy of metastatic HER2 positive 
breast cancer, improved progression free survival (PFS) and overal surival (OS) by almost 16 months, with 
median survival od almost 5 years. This combination is now established as preffered first-line regimen. 
Before pertuzumab small peroral tyrosine kinase inhibitor(TKI), lapatinib was in routine practice for 
advanced disease. Lapatinib is reversible inhibitor of HER1 and HER2 kinases. In combination with 
capecitabine, it showed improved PFS compared to capecitabine alone, but no efficacy was found on OS. 
Trastuzumab-emtansine(T-DM1) is an antibody-drug conjugate (ADC), comprised of trastuzumab and 
maytasine derivate,an antimitotic agent. Conjugate is, after binding to HER2 receptor, internalized, 
degraded in the lysosomes,releasing active payload and resulting in tumor cell death. T-DM1 significantly 
improved PFS and OS in patients with advanced disease, previously treated with trastuzumab, when com-
pared to combination of lapatinib and capecitabine. TDM-1 is now standard second-line treatment of meta-
static HER2 positive breast cancer. There is no standard treatment in third or subsequent lines of therapy. 
Treatment options include lapatinib,capecitabine, combinations of trastuzumab with chemotherapy, dual 
anti-HER2 therapies, combination of HER2 and hormonal therapy in endocrine positive tumors. Unfortu-
nately, vast majority of patients develop progressive disease, and high proportion, up to 50% of patients, 
develop brain metastases. A number of novel anti-HER2 treatments have been developed and studied.
Tyrosin-kinase inhibitors
Neratinib: pan-HER inhibitor,irreversibly binding to HER1, HER2, and HER4, approved as extended 
adjuvant therapy in early HER2 positive BC. In metastatic setting, several trial tested its efficacy. In 
NEfERT-T trial, combination of neratinib+paclitaxel was compared to trastuzumab+paclitaxel. It did not 
show superiority, but the incidence of brain metastases was significantly lower in neratinib arm, as well as 
significantly delayed. Another phase II trial TBCRC 022, with combination of neratinib and capecitabine 
showed reduction of CNS lesions of 49%. NALA, phase III study, compared nerabinib+capecitabin with 
lapatinib+capecitabine in heavily pretreated patients. Combination with neratinib improved PFS, delayed 
the time to intervention for CNS disease and reduced risk of progression or death by 24%. At 12 months 
PFS was 29 for neratinib vs 15% for lapatinib arm.
Tucatinib: an oral TKI with high selectivity for kinase domain of HER2 receptor and minimal inhibi-
tion of EGFR. Its efficacy was demonstrated in HERCLIMB, phase II study. It included heavily pretreated 
patients, with or without brain metastases, that previously received trastuzumab, pertuzumab and TDM1. 
At 12 months PFS was 33% in tucatinib arm vs 12.3%. median duration of PFS was was 7.8 months and 5.6 
months and OS rate at 2 years was 44.9% in the tucatinib arm vs 26.6% in the placebo arm. Among the 
patients with brain metastases, PFS rate at 1 year was 24.9% in the tucatinib arm and 0% in placebo arm.
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Pyrotinib: an ireversible pan-HER TKI that showed superior efficacy in combination with capecitabine, 
compared to lapabinib with capecitabine. In patients that received at least two previous lines of therapy, 
ORR was 78.5% in pyrotinib arm vs 57.1% in lapabinib arm, and median PFS of 18 months vs 7 months 
with lapatinib.
Antibody-drug conjugates (ADCs)
Antibody-drug conjugates: combination of monoclonal antibodies (MAbs) and potent cytotoxic 
drugs. Specific antibodies bind to receptor expressing tumor cells and deliver toxic agents more selectively 
causing death of tumor cells. The first in the class was T-DM1 and its efficacy led to development of vari-
ous other anti-HER2 ADCs. Cleveable linker of newer ADCs, (oposite to non-cleveable linker in TDM1), 
mediates bystander killing effect of surrounding cancer cells via passive diffusion of cytotoxin into tumor 
microenvironmentm killing cells insensitive to antibody, but sensitive to cytotoxic drug linked to it.
Trastuzumab deruxtecan (DS-8201) is a conjugate of trastuzumab linked to a payload of topoisomerase 
1 inhibitor exatecan. DS-8201 showed ORR of 54.5% in patients pretreated with TDM-1,trastuzumab and 
pertuzumab. DS-8201 also showed activity in low HER2 expressing tumors, with ORR of 50%. Trial DES-
TINY-Breast01, included patients with HER2 positive cancer that were previously treated with TDM-1 and 
trastuzumab, 66% also received pertuzumab. DS-8201 treatment showed ORR of 60.3%, with CR rate of 4.3%. 
Median PFS was 16.4 months. Serious side-effects were ILD in 9% and pneumonitis, fatal in 2.6% of patients.
SYD985: conjugate of trastuzumab linked to a duocarmycin payload (in prodrug form). After endo-
cytosis, linker is cleaved and duocarmycin payload is released causing irreversible DNA alkylation in 
tumor cells. In breast cancer, study included patients with HER2+ and HER2-low breast cancer. Most 
HER2 positive patients received 3 and more prior regimens (80% T-DM1). SYD985 demonstrated ORR of 
33% and a median PFS of 9.4 months.Efficacy was seen also in heavily pretreated HER2-low, HER+ and 
TNBC patients. The ORRs were 27% and 40%, respectively.A Phase III study (TULIP) is currently ongoing 
comparing SYD985 vs therapy of physicians choice.
HER2 antibodies
Margetuximab binds to the same epitope as trastuzumab, but significantly stronger to effector cells 
with more effect on antibody-dependent cell-mediated cytotoxicity (ADCC).Phase III SOPHIA trial, com-
pared margetuximab plus chemotherapy with trastuzumab plus chemotherapy. Median OS was 26.1 
months with margetuximab compared with 19.8 months treated with trastuzumab. Margetuximab sig-
nificantly improved ORR 25.2% vs 13.7%, and CBR was 48.1% compared with 35.6% in trastuzumab arm. 
CR was observed in 1.2% of patients. The median PFS was 5.7 months versus 4.4 months the trastuzumab 
group. The risk of disease progression or death was decreased by 29%.
A novel class of antibodies are bispecific antibodies, targeting two different epitopes, either in same 
or in different receptors. MCLA-128 targets both HER2 and HER3, and in phase I/II showed clinical ben-
efit in 6 heavily pretreated patients with median of 5 prior lines of therapy for metastatic disease. Two 
phase II studies are ongoing in combination with trastuzumab+/-chemotherapy and in combination with 
endocrine therapy in HR+ but HER2-low breast cancer. ZW25 binds to different epitopes of HER2 extracel-
lular domains 2 and 4, with increased activity even in HER2 low expressing tumors.
Combinations with other agents
Since anti HER2 monoclonal antibodies mechanism of action include ADCC and adaptive immunity, 
many trials studied efficacy of combination of antiHER2 therapies and checkpoint inhibitors. Combination 
of pembrolizumab and trastuzumab in PANACEA study, phase Ib/II, demonstrated an ORR of 15.2% in 
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PD-L1 positive patients. In phase II trial, KATE2, combination of atezolizumab and T-DM1 did not 
improved PFS compared to T-DM1 alone, but efficacy was more profound in PD-L1 positive and stromal 
TIL+ subgroups.
Many studies showed sinergistic action between CKD4/6 inhibitors and anti-HER2 therapy. Ongoing 
trials are evaluating role of CDK4/6 in HER2+ disease. The phase II monarcHER trial evaluated abemaci-
clib+ trastuzumab+fulvestrant in heavily pretreated patiens with HR/HER2 positive breast cancer. The 
triplet had a median PFS of 8.3 compared to 5.7 months for trastuzumab plus chemotherapy and risk 
reduction for disease progression and death by 33%.PATINA study explores role of palbociclib in addition 
to trastuzumab, pertuzumab and AI, while SOLTI-1303PATRICIA trial evaluates combination of palboci-
clib, trastuzumab +/-letrozole in metastatic HER2+ patients. Many other trials combine anti HER2 thera-
pies (TKIs,ADCs) with CD4/6 inhibitors and endocrine therapy.
In recent years data showed close relation of HER2 and PI3K/AKT/mTOR pathway. PI3K inhibition 
enhances HER2 signaling, so there was a rationale that the combination could overcome the resistance to 
HER2 therapy. Studies with mTOR inhibitor everolimus BOLERO-1 (combination with trastuzumab, 
paclitaxel) and BOLERO-3(combination with trastuzumab and vinorelbin) did not show desired efficacy, 
although improved PFS was seen in patients with PIK3CA mutations. Alpelisib is α specific PI3K inhibitor 
evaluated in several trials with trastuzumab and T-DM1. Phase I study with TDM1 in heavily pretreated 
patients showed activity (ORR of 43%), even in T-DM1 resistant patients (ORR of 30%, CBR 60%).
Interesting therapy approach are HER2 targeting vaccines, since bulk of patients have HER2 low 
expression and do not benefit from HER2 therapy. Nelipepimut-S (NPS) is HER2 derived peptide, com-
bined with GM-CSF, evaluated in phase II trials with trastuzumab in HER2 3+,HER2 1+ and 2+ tumors. 
Peptides are recognized as an antigen that stimulates the production cytotoxic T lymphocytes (CTLs), 
which destroy tumor cells expressing tHER2 antigen while GM—CSF boosts the number of immune cells. 
In study that included HER2+ and even TNBC patients had two arms. Patients received trastuzumab + 
GM-CSF +/- NPS. In NPS arm, DFS was slightly improved, 89.8% vs 83.8% respectively. At 36 months, the 
DFS rate was 86.7% with NPS and 80.8% without it. More profound benefit was seen in TNBC patients: 
24-month DFS was 92.6% with NPS vs 70.2% without NPS.
As majority of patients experience disease progression, the need for new therapies is recognized. Many 
anti-HER2 agents have been, and are being developed; different combinations with CDK4/6 inhibitors, PI3K 
inhibitors, checkpoint inhibitors and vaccines are being explored - both approaches with promising results.
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S6 - THE OPTIMAL TREATMENT OF METASTATIC TRIPLE NEGATIVE 
BREAST CANCER
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Triple-negative breast cancer (TNBC) is defined by lack of expression of estrogen receptor, progester-
one receptor and HER-2 amplification and accounts for approximately 15-20% of breast cancers. It is also 
a heterogeneous group of tumors which tend to have an aggressive phenotype with higher recurrence 
rates and lower survival rates. Metastatic TNBC is associated with poor prognosis and limited treatment 
options. Although chemotherapy has been the main treatment option for metastatic TNBC for a long time, 
this scenario has changed with the recent efficacy data on the polyadenosine diphosphate-ribose poly-
merase inhibitors (PARPis) for patients harboring a mutation in the BRCA genes (BRCAmut) and also with 
the results of immunotherapy agents in patients with PD-L1-positive tumors.
However, TNBC is known to be more immunogenic compared to other breast cancer subtypes, with 
tumor-infiltrating lymphocytes playing an important prognostic and predictive role. Response rates to 
single agent immune checkpoint blockade in unselected pretreated HER2-negative metastatic breastcan-
cer (MBC) are low. However, they may be augmented when combined with chemotherapy. Immuno-
therapy agents in combination with systemic chemotherapy have been shown to alter the natural history 
of this devastating condition, particularly in patients whose tumors are positive for programmed cell 
death ligand 1 (PD-L1).
The safety and efficacy data from the phase III Impassion 130 trial have led to FDA and EMA approval 
of atezolizumab and nab-paclitaxel for patients with tumous tested positive for PD-L1 by the Ventana 
SP142 companion diagnostic immunohistochemical assay. It is an important advance for treatment of 
metastatic TNBC. However, ongoing investigations need to define better biomarkers of response, deter-
mine resistance mechanisms, and identify strategies to increase response rates. Chemotherapy- free com-
binations are also under the evaluation. Results presented on ESMO 2019 Congress from the phase I/II 
MEDIOLA trial supported the combination treatment of olaparib and durvalumab in the treatment of 
patients with germline BRCA-mutated metastatic breast cancer.
In patients without a BRCA mutation and with PD-L1-negative tumous, single-agent chemotherapy 
with taxanes (paclitaxel or docetaxel) as a first-line treatment is recommended. In patients with a high 
disease burden or who are symptomatic, combinations such as anthracyclines plus cyclophosphamide or 
platins with taxanes are valid options. While numerous studies investigating anti–vascular endothelial 
growth factor (VEGF) therapy suggest improved progression-free survival, studies to date have not dem-
onstrated a survival benefit in the metastatic setting.
The androgen receptor (AR) has been identified as a possible predictive biomarker for antiandrogen 
therapy in ER- breast cancer. AR positivity has been associated with more favorable prognosis in TNBC. 
There are several studies that show AR is associated with lower Ki-67 proliferative marker, lower mitotic 
score, lower histologic grade and lower clinical stage. Biological insight into AR-positive breast cancer reveals 
that AR may cross-talk with several vital signaling pathways, including key molecules and receptors.
Despite recent treatment advances, metastatic TNBC remains aggressive disease with poor progno-
sis. The treatment of TNBC is constantly evolving, and the inclusion of patients in ongoing clinical trials 
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evaluating new targeted agents against cell surface antigens, immunotherapy agents and predictive bio-
markers should be encouraged.
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S7 - A CASE REPORT OF LUMINAL BREAST CANCER
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This report describes the case of a 54-year-old female with breast cancer. In July 2016, she had noticed 
a mass in the right supraclavicular fossa. She was referred to our institution. Suspected primary tumor of 
the right breast with right supraclavicular, right retropectoral, right axillary, right parasternal and medias-
tinal lymph node metastases was revealed by positron-emission tomography (PET/CT). Pathological analy-
sis of the extirpated supraclavicular lymph node revealed metastatic cancer. Estrogen receptors (ER) were 
positive in 100% of the tumor cells, progesterone receptors (PR) were positive in 20% of the tumor cells and 
human epidermal growth factor receptor 2 (HER2) status was negative. Ki-67 proliferation index was 
25-30%. She was originally treated with endocrine therapy: letrozole (8/2016-8/2017); tamoxifen (8/2017-
11/2017); ribociclib and exemestane (11/2017-6/2018). Then, in June 2018 patient presented with respiratory 
symptoms (cough and dyspnea), right shoulder and arm pain. There were palpable lymph nodes in the 
right supraclavicular fossa measuring about 4 centimeters in diameter on physical examination. Multi-slice 
computed tomography (MSCT) of the chest showed progression of the disease (conglomerate lymph node 
masses of the right axilla, right infraclavicular and right supraclavicular region). Patient underwent pallia-
tive three-dimensional conformal radiation therapy (3D CRT) of the right axillary and right supraclavicular 
lymph nodes in total dose (TD) of 25 Grays (Gy) in 5 fractions and after that started treatment with 
capecitabine chemotherapy (patient preference for oral chemotherapy). At that time patient also presented 
with pain of the right femur. A bone scintigraphy showed metastases in right occipital bone, sternum, right 
femur. Patient underwent palliative 3D CRT of the right femur (lesser trochanter and diaphysis) in TD 8 
Gy/1 fraction. She was also treated with bisphosphonates. In November 2018, progression of the disease 
was detected on diagnostic workup (tumor infiltration of the superior and middle lobe in the right lung). 
Patient was treated with chemotherapy-weekly paclitaxel. Bronchoscopy with biopsy was also performed. 
Pathological analysis revealed metastatic breast cancer (ER 100%, PR 10%, HER2-negative). In April 2019, 
due to further progression of the disease in right lung, patient underwent palliative 3D CRT of the right 
lung mass (TD 20 Gy/5 fractions). In July 2019, patient achieved radiographic partial response. In August 
2019, multiple small nodules of the right breast were detected by mammography and breast ultrasound. 
Core-biopsy was performed and pathological analysis revealed breast cancer (ER 100%, PR negative, HER2-
positive; Ki-67 50-65%). Patient was treated with chemotherapy-gemcitabine and dual HER2-directed ther-
apy (trastuzumab and pertuzumab). After 6 months of treatment, the patient achieved radiographic stable 
disease. It has been reported earlier that HER2-positive cancers may become negative following treatment 
with trastuzumab (1), but transformation of cancer status from HER2-negative to positive has not been 
extensively studied (2). A patient whose breast cancer changed from HER2-negative to positive, following 
treatment, was described in this case report. Re-biopsy therefore may be of necessity, during breast cancer 
treatment course, in order to re-asses the HER2 status. In this way the clinician is given the opportunity for 
HER2-directed therapy inclusion, for patients with transformation to HER2-positive cancer.
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SUPPORTIVE THERAPY
S8 - MANAGEMENT OF CANCER PAIN
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Cancer pain can be caused by the tumor itself, surgery, or is the result of chemotherapy or radio-
therapy treatment. Neurological post-therapy impairments (due to radiation and chemotherapy) are sig-
nificant causes of pain in cancer pain syndrome. These impairments often present up to 20% of total cancer 
pain. The most common clinical appearance of post-therapy complication is sensory and motor symmetri-
cal polyneuropathy as a result of impaired axonal neurotransmitters transport and degeneration or seg-
mental demyelination of axons. Besides peripheral painful neuropathies, asymmetrical focal or symmetri-
cal distal poly-neuropathy, lesions in the central and autonomous nervous system are also possible. In 
accordance with these facts, appearance of symptoms like paresthesia, dysthesia, numbness and burning 
together with attenuation or disappearance of reflexes are warnings of toxicity ofapplied cancer therapy. 
Considering pharmacotherapy, conventional analgesics are not effective. Because of that, neuropathic 
pain treatment is composed of four different groups of drugs (anticonvulsant, tricyclic antidepressant, 
opoid, drugs for topical use). It isadvantageous to combine drugs with different mechanisms of action 
(rational polypragmasia).
Optimal pharmacologic management can achieve adequate pain control in 80-85% ofpatients. 
Exhausting, ineffective drug therapy often only increases the suffering of patients and significantly reduces 
the quality of life. The need for more invasive modalities should be infrequent. Invasive procedures to 
treat pain have their place in the algorithms for treatment that are presented as a conversion chart WHO 
for the treatment of cancer pain. Celiac plexus blockade is classically designed to treat very severe pain 
caused by cancer pancreas, gallbladder, liver, stomach, small intestine, omentum, mesentery and upward 
and lateral part of the colon. Neurolytic celiac plexus block leads to a long-acting improvement in 70-90% 
of patients with pancreatic cancer and other cancers in the abdomen. Superior hypogastric plexus block is 
used in patients who have pain in the pelvic viscera. Usually superior hypogastric neurolysis is used in a 
very strong visceral pelvic pain malignant origin. Patients with local invasion of cancer of the vagina, 
uterus, ovary, prostate and rectum that are associated with pelvic pain often have a significant reduction 
in pain after the blockade or neurolysis a superior hypogastric block. Block gangion impar is indicated in 
cocigodinia, pain anorectal and perineal region due to malignant disease in the rectum, and after abdomi-
nal perineal resection of rectal cancer or pain as a result of radiation in this area. Intrathecal drug is reserved 
for patients with very severe pain that does not respond to conservative therapy.
Many patients with cancer suffer severe pain despite opioid peptide therapy or have unacceptable 
side effects due to the use of opioids. Intrathecal opioids significantly reduce pain in these patients, 
and the side effects are much less compared to other routes of administration of opioids. Continuous 
delivery of morphine and other opiates is possible to install percutaneous catheter intrathecal or epidural 
space.
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S9 - OPTIMAL TREATMENT OF STAGE III NON-SMALL CELL LUNG 
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The appropriate treatment of stage III non-small cell lung cancer (NSCLC) patients is a huge chal-
lenge in our everyday clinical practice due to patients’ heterogeneity and the complexity of the available 
therapy modalities. Also, there is no clear consensus about the most efficient treatment for one part of such 
patients. In the light of that, a basic precondition for good results in the treatment of stage III NSCLC 
patients is a well organized multidisciplinary team.
Surgical treatment as a primary, inital treatment option is indicated in just a small number of those 
patients. The most efficient treatment for the majority of patients with good general condition is concur-
rent chemoradiotherapy (CRT). The median overall survival for them is of about 25 months. Once it was 
concluded that the concurrent CRT was the optimal therapeutical approach, a series of clinical studies 
followed, which throughout more that 10 years of research brought no further success in the treatment of 
stage III NSCLC patients. In some of those studies induction or consolidation chemotherapy was added to 
the concurrent CRT, while other studies investigated the efficacy of platinum-based chemoterapeutic pro-
tocols modifications in concomitance with radiotherapy (paclitaxel or pemetrexed applied instead of eto-
poside). Despite great expectations from the significant techological improvements in the radiotherapy 
field, with the increase of tumor dose from 60 to 74 Gy we did not obtain better effieciency, but just higher 
toxicity. Furthermore, we do not have any evidence that the overall survival improves with the surgical 
treatment after the chemo(radio)therapy. Finally, in phase III clinical study, when the patients who were 
treated with the concurrent CRT started to receive consolidation therapy with durvalumab or placebo, a 
long awaited progress was reached. The median progression-free survival increased significantly with 
durvalumab (5,6 months versus 16,8 months, HR 0,52, p<0,001), just like the overall survival (HR = 0,68, 
95% CI 0,53-0,87, p=0,00251, median not reached with durvalumab versus 29,1 months with placebo).
It is important to mention that neoadjuvant immunotherapy shows very promising results. For exam-
ple, in phase II trial neoadjuvant treatment with ipilimumab (one cycle) and nivolumab (three cycles) in 
44% of patients with stage I-III (single N2) resectable NSCLC resulted with major pathological response 
(MPR, tumors with no more than 10% viable tumor cells). Even more impressive results are obtained with 
neoadjuvant chemoimmunotherapy. In phase II trial, 3 cycles of nivolumab, paclitaxel and carboplatin in 
patients with resecable stage III A (N2) NSCLC resulted with MPR in 83% of patients, 58% of patients had 
a complete pathologic response.
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EGFR mutations in lung carcinoma are a well established and studied molecular target for tirosin 
kinase inhibitor therapy. There are three generations of EGFR inhibitors (EGFRi) available, two of which 
are used for first-line treatment: erlotinib, afatinib and gefitinib. All of them showed significantly better 
PFS compared to platinum- based chemotherapy (ChT) in their registrational studies, with nos OS benefit 
due to a high crossover rate. (1-3) Subsequent real world data support these findings, without any prefer-
ence between first and second generation EGFRi. The 3rd generation EGFRi, osimertinib, was first to show 
statistically significant benefit in PFS and OS compared to other EGFR TKIs (erlotinib and gefitinib) in the 
FLAURA study (mPFS 18.9 versus 10.2 months; HR 0.46, 95% CI 0.37–0.57), and the benefit was observed 
also in patients with CNS metastatses (mPFS 15.2 vs 9.6 months, HR 0.47, 95% CI 0.30–0.74), which makes 
osimertinib now the preferd TKI in first-line setting. (4)
After progression on 1st and 2nd generation EGFRi, a newly aquired, exon 20 T790M mutation is 
responsible for TKI resistance in about 50% of cases. It can be detected by tissue rebiopsy or liquid biopsy, 
analyzing circulating tumor DNA. In the AURA3 study, osimertinib was compared to platinum- based 
ChTshowing significant benefit in PFS (10.2 versus 4.4 months; HR 0.30, 95% CI 0.23–0.41). (5) If the resis-
tance is acquired via other mechanisms, ChT remains standard of care to date, although other targeted 
therapies show promising results, but currently without EMA approval.
Treatment of ALK-rearranged NSCLC
ALK tyrosine kinase inhibitors (ALK TKIs) are recommended treatment options for ALK-rearranged 
NSCLC. Crizotinib, a first-generation ALK TKI showed superiority over platinum-based chemotherapy 
(ChT) in the first line setting. (6) Alectinib, a second-generation ALK TKI is a better treatment option than 
crizotinib or ChT based on ALEX and J-ALEX studies where it was shown that mPFS with alectinib was 
34.8 (95% CI 17.7–NR), compared with 10.9 months (95% CI 9.1–12.9) with crizotinib. In patients with 
baseline CNS metastases, mPFS was 27.7 months for alectinib versus 7.4 months for crizotinib. The time to 
CNS progression was significantly longer with alectinib than with crizotinib. (7, 8) In patients with CNS 
involvement, front-line use of ALK TKIs is effective with the highest ORR seen with alectinib or ceritinib. 
Brigatinib was compared to crizotinib in ALTA-1L trial where HRs favoured brigatinib with mPFS at 12 
months 67% for brigatinib and 43% for crizotinib (HR 0.49, P<.001). (12) Patients that are progressing on 
crizotinib should receive next-generation ALK TKIs, such as alectinib, ceritinib, or brigatinib (based on the 
data from ASCEND-5, ALUR and ALTA studies). (10-12) In patients previously treated with one or more 
second-generation ALK TKIs, a high proportion of patients responded to lorlatinib, a third-generation 
ALK TKI, a recommended after progression on first or second-generation ALK TKIs. (12)
Treatment of ROS1-rearranged NSCLC
Crizotinib, a first-generation ALK TKI that also inhibits ROS1 was evaluated in ROS1-rearranged 
NSCLC in few phase I and II studies, where crizotinib showed superior efficacy over platinum-based che-
motherapy (ORR 72-80%, mPFS 9.1-19.2 months). (13) Ceritinib also showed superiority in patients with 
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ROS1-rearranged advanced NSCLC, especially in crizotinib-naive patients (ORR was 67%, with a disease 
control rate of 87%. The mPFS was 9.3 months for the entire cohort and reached 19.3 months for crizotinib-
naive patients). (14) Brigatinib, lorlatinib, repotrectinib and entrectinib also have potential anti-ROS1 
activity based on limited phase I and II studies. (12, 15, 16)
Treatment of NSCLC bearing other driver mutations
A B-RAF mutation, V600E is detected in 1-2% of lung adenocarcinomas. Both NCCN and ESMO rec-
ommend a BRAF/MEK inhibition therapy using dabrafenib in combination with trametinib as a first line 
treatment for these patients. (17)
Several other molecular targets have been detected in NSCLC, including HER2 or MET dysregulation 
via a number of possible mechanisms or RET or NTRK fusion, but targeting these pathways in NSCLC is 
currently not recommended
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Lung cancer is the most common cause of cancer death in the world. ALK (Anaplastic Lymphoma 
Kinase) gene rearrangements is present about 5% of patient with non small cell lung cancer (NSCLC) (1). 
Crizotinib is ALK inhibitor which is in randomised phase 3 trials has shown superior progression-free 
survival (PFS, median 10.9 months) in patients with previously untreated advanced ALK-positive NSCLC 
(2). We present a case of ALK-positive metastatic lung cancer that after remarkably decreased disease 
maintained stable disease over 34 months with crizotinib.
In February 2017 a 50 year old female with smoking history 10 cigarettes per day for 20 years pre-
sented with cough and headache. Past medical history revealed hypertension. Chest CT detected right 
sided lung cancer with metastases to the right hilum, mediastinum and right supraclavicular lymph nodes, 
esophageal compression and minor pleural effusion right. Brain MRI showed multiple brain metastases. 
Pathology revealed adenocarcinoma by bronchoscopy and fine needle aspiration cytology of supracla-
vicular lymph nodes. Molecular testing was positive for ALK mutation and epidermal growth factor 
receptor (EGFR) mutation negative. The clinical stage was IVB according to the TNM classification. Patient 
treated with palliative whole brain radiotherapy to a dose of 30 Gy in 10 fractions. In April 2017, patient 
started treatment with oral crizotinib, at a dose of 250 mg twice daily. After 2 weeks of treatment complete 
remission of metastasis in right supraclavicular lymph nodes was verified by physical examination and 
forceful productive cough with expelling necrotic secretions. Follow-up chest CT and brain MRI imaging 
after a two month showed disease was decreased remarkably. Stabile disease was confirmed after 2 months 
and maintained over 34 months after the starting treatment with crizotinib. Treatment-related adverse 
events were rash, visual disturbance, nausea, dysgeusia, peripheral edema and elevation in serum of lac-
tate dehydrogenase (LDH) isoenzymes with aspartate transaminase (AST).
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A 60-year-old patient, who had no previous illness or any chronic therapy, was treated for right-sided 
pleuropneumonia at the end of December 2018. He complained of coughing and sensation of stabbing in 
his right chest. He was treated with ciproflosacin and then levofloxacin, but regression did not occur with 
antibiotic therapy. Thoracic MSCT verified centrally located expansive formation of the right upper pul-
monary lobe infiltrating the lobar bronchus with consequent atelectasis, extensive mediastinal lymphade-
nopathy up to 2.2 cm (pretracheal), and right dorsobasal pleural effusion up to 4.5 cm. Cytologically, no 
malignant cells were found in the pleural effusion, and the finding suggested a lymphocytic type of effu-
sion. Bronchoscopically taken sample was investigated pathohistologically and lung adenocarcinoma was 
diagnosed. He was presented on the multidisciplinary lung tumor team on January 30, 2019, and it was 
recommended to wait for the resaults of the EGFR testing and to start pembrolizumab treatmen in case of 
negative findings and positive pleural effusion (malignant cells). No malignant cells were found cytologi-
cally in the repeated pleural effusion sample. In the meantime, he noticed that he could not close the right 
eye and had weakness in his right hand. On February 1, 2019, a brain MSCT was performed to describe: 
left frontal marginally imbibed annular secondary lesion 15 mm in diameter and right parasagittal parietal 
with a 13 mm diameter near falx, with a wider area of edema. He was presented again on the multidisci-
plinary lung tumor team on February 6, 2019, and was advised to begin pembrolizumab immunotherapy 
with a brain MRI for a possible gamma knife treatnent of the brain metastases. After the brain MRI was 
done on March 25, 2019, he was treated with gamma knife (4 intracranial metastases) at KBC Zagreb (pre-
scription doses 22-24 Gy to prescription isodoses 50-78%). On April 18, 2019, after the application of three 
cycles of pembrolizumab, he underwent the first control MSCT of the thorax and upper abdomen, which 
described a complete regression of pleural effusion, significant regression of lymphadenopathy with a few 
remaining minor lymph nodes, and suspected collication within the upper right lobe consolidation. Based 
on this, he was presented again on the multidisciplinary team for lung tumors on April 24, 2019 and it was 
recommended to continue pembrolizumab immunotherapy. From June 3 to June 11, 2019, he was hospital-
ized for bilateral pulmonary embolism and has since been taking NOAK therapy. During hospitalization, 
he started taking therapy for iatrogenically provoked newly diagnosed diabetes mellitus. He was regu-
larly presented on the multidisciplinary lung tumors team after every three cycles of pembrolizumab with 
the control MSCT of the thorax and upper abdomen which showed every time further regression of the 
primary tumor and mediastinal lymph nodes or a stationary finding in comparison with previous, and the 
team’s recommendation was to continue immunotherapy with pembrolizumab. In addition, he had two 
control brain MRIs that showed good growth control of all treated meta changes and did not verify any 
new secondaryisms. He was last shown on athe multidisciplinary team for lung tumors on February 19, 
2020 with control MSCT of thorax and upper abdomen which was stationary and it was recommended to 
continue pembrolizumab immunotherapy. By February 27, 2020, he had received 16 cycles of pembroli-
zumab. He also feels subjectively fine and does not complain of significant dyspnoic problems. He toler-
ates effort quite well, didn’t cough and was not febrile. He had no side effects of immunotherapy.
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Historically, the biggest problem in locally advanced rectal cancer is not distant recurrence. It is high 
rate of locoregional recurrence – up to 50%. First clinical trials tried to decrease this rate. As a result of 
clinical trials, in 1990 a consensus of using trimodality treatment (chemotherapy, radiotherapy and sur-
gery) was reached. Using this approach local recurrence rate was decreased to 5-6%.
First trial of adjuvant radiotherapy in combination with fluoropyrimidines was Fisher et al from 1988. 
Local recurrence rate was decreased, but rate of distant recurrence remain the same.
In 2004, the results of big German trialon 832 patients was published, and in 2012 the results from the 
same trial after 11 years of follow up. This trial concluded that the local recurrence rate was significantly 
reduced in the preoperative group of patients (6% vs 13%; p=0.006), whilst toxicity was lower and the 
patients receiving neoadjuvant chemotherapy had better quality of life. However, no difference in overall 
survival rates have been observed.
The next question to answer was is there any difference in the terms of benefit in DFS, OS, and local 
control of disease, between SCRT (5 fractions of 5 Gy) and immediate surgery and LCRT (5 weeks of radio-
therapy) and delayed surgery. The difference between these two modalities was in pathological complete 
response rate, but that was not surprising according to immediate surgery. These is important because of 
more often sphincter preserving in LCRT and delayed surgery group. At the other side there was no dif-
ference in local control, DFS and OS.
According to more often sphincter preserving in delayed surgery group big Stockholm III trial com-
pared effects of SCRT with immediately and SCRT with delayed surgery. This trial showed that delayed 
surgery after SCRT has similar effects as immediately surgery after SCRT.
In 2017 we had results of study that compared SCRT and LCRT with adding of chemotherapy (fluo-
ropyrimidins) and delayed surgery. This trial has confirmed that short course neoadjuvant chemoradio-
therapy is safe and efficient treatment modality, and the results are comparable with standard long course 
neoadjuvant chemoradiotherapy.
At the other hand there are patients with pathological complete response after neoadjuvant therapy 
and that patients caan maybe be candidates for „watch and wait“ approach, and this is subject of current 
clinical investigation. Also new trials are planning to explore the use of other radiosenzitizing agents in 
neoadjuvant setting.
We have significant advancements in the management of locally advanced rectal cancer in last 30 
years, resulting in improved local control rates, but risk of distant metastases remains an onging problem. 
We hope that new strategies in selecting patients for chemoradiotherapy or upfront chemotherapy should 
result in decreased morbidity for some patients.
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Introduction
The last decade we has witnessed great progress in understanding the immune response of tumors, 
spilling over into numerous studies of modern immunotherapy, primarily with anti PD1 monoclonal anti-
bodies, in various malignancies with improved objective response rate (ORR), duration of response, pro-
gression-free survival (PFS) and overall survival (OS). This summary will outline the most important 
immunotherapy studies in gastrointestinal tumors.
Cancer of the esophagus and gastroesophageal junction
Based on a Phase III (TOGA) study and an improvement in overall survival (2.8 months gain in 
median OS, p = 0.046) over standard polychemotherapy, today’s standard in the first line of treatment for 
advanced HER2 positive esophageal adenocarcinoma and esophagogastric junction (EGJ) is combination 
of cisplatin and fluoropyrimidine-based chemotherapy in combination with trastuzumab (1). The benefit 
was particularly observed in patients with HER expression of IHC3 + and IHC2 + and FISH positivity (4.2 
months gain in median OS) (1). In the second line of treatment, in the same group of patients (regardless 
of HER2 status), considering first-line therapy and general patient status, ramucirumab monotherapy 
became the standard (REGARD study; 1.4 month gain in median OS versus placebo, p = 0.047) or in com-
bination with paclitaxel (RAINBOW study; 2.3 months gain in median OS relative to paclitaxel alone, p = 
0.007) (2.3).
Pembrolizumab, an anti PD1 monoclonal antibody, is the preferred treatment option in the second or 
later lines of MSI-H / dMMR tumors based on KEYNOTE-016 study with ORR of 71% and PFS rate of 67% 
at 20 weeks (4). Pembrolizumab is also a second-line therapeutic option for esophageal squamous cell 
carcinoma showing PD-L1 expression with CPS ≥ 10 (KEYNOTE-061, KEYNOTE-180 and 181) and third-
line esophageal and EGJ adenocarcinoma with PD-L1 expression of CPS ≥ 1 (KEYNOTE -012) (5,6,7). First-
line studies of pembrolizumab alone or in combination with cisplatin and 5-FU chemotherapy in patients 
with advanced EGJ cancer (KEYNOTE-059) are ongoing, as well as a study of the combination of pembro-
lizumab and cisplatin chemotherapy and 5-FU in patients with advanced adenocarcinoma, squamous cell 
carcinoma of the esophagus and adenocarcinoma of EGJ (KEYNOTE-590) (8,9).
Another anti-PD1 monoclonal antibody, nivolumab, in monotherapy or in combination with CTLA 4 
antibody ipilimumab, showed activity in the treatment of advanced esophageal cancer and EGJ cancer, 
but has not yet become part of standard guidelines (CheckMate-032 study) and we need larger phase III 
trials (10). A phase III study, CheckMate 649, is ongoing, comparing nivolumab plus ipilimumab with 
nivolumab plus chemotherapy and chemotherapy alone in the first line of treatment. Due to the high inci-
dence of high-grade toxicity in the nivolumab plus ipilimumab combination, enrollement in this study 
arm was terminated (11).
Avelumab, an anti PD-L1 monoclonal antibody, in a phase III study, Javelin Gastric 300, did not show 
better median PFS and OS compared with third-line chemotherapy (12). The Javelin Gastric 100 study is 
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ongoing, where avelumab is being tested as a maintenance therapy in monotherapy, in the first line of 
treatment (13). MSI-H/dMMR and PD-L1 status should be assessed in all esophageal and EGJ adenocarci-
noma if metastatic disease is suspected.
Gastric cancer
For many years, the median OS of advanced or metastatic gastric cancer did not change and ranged 
from 9 to 11 months. With the combination of first-line cisplatin and fluoropyrimidine-based chemother-
apy and trastuzumab, the median shifted to 11 months and in selected patients (high HER2 expression) to 
16 months (1). Also, ramucirumab, in monotherapy or in combination with paclitaxel, has become the 
standard option in second-line treatment (2,3). In recent years we have witnessed the role of new immu-
notherapy (anti PD1 monoclonal antibodies) in the treatment of this group of patients. Pembolizumab has 
gained an FDA-accelerated approval in 2017 for the treatment of patients with advanced and metastatic 
MSI-H or dMMR gastric cancer who have progressed to previous therapy or have no other treatment 
options (14). In 2017, the FDA also approved pembrolizumab for patients with advanced or metastatic 
gastric or EGJ cancer who progressed to prior cisplatin and fluoropyrimidine-based chemotherapy and 
HER2 immunotherapy. The approval was based on studies KEYNOTE-012 and KEYNOTE-059. KEY-
NOTE-016 is a Phase Ib study evaluating pembrolizumab in patients with PDL1 positive recurrent or 
metasatic gastric or EGJ adenocarcinoma. The ORR was 22 and 13%, respectively. The results of this study 
confirmed the results of the KEYNOTE-059 study with cohort I with 259 patients with gastric or EGJ ade-
nocarcinoma who had progressed to previous chemotherapy. The ORR was 15% with 2% of patients with 
complete remission and a median duration of response of 16 months. A cohort 2 and 3 examining pembro-
lizumab in the first line of treatment as monotherapy or in combination with chemotherapy was included 
in the same study. Pre-eliminated data show promising results both in monotherapy and in combination 
as well as an acceptable toxicity profile (8,15). In a Phase III study, KEYNOTE-061, pembolizumab was 
compared with paclitaxel in 395 patients with PD-L1 CPS ≥ 1 who had progressed to previous therapy. In 
thist study pemborlizumab did not statistically significantly improve median OS of patients with pacli-
taxel (9.1 vs 8.3 months), but had a better toxicity profile and was better tolerated than paclitaxel (5). In 
addition to pembrolizumab, other checkpoint inhibitors (nivolumab, avelumab) have been studied in this 
group of patients and the results are presented in the section with esophageal and EGJ cancer, since stud-
ies with these drugs included patients with advanced or metastatic gastric cancer (10-13).
Colorectal cancer
For more than a decade, immunotherapy (bevacizumab, aflibercept, cetuximab, panitumumab, ramu-
cirumab, trastuzumab) in combination with numerous chemotherapy protocols (based on irinotecan, 
oxaliplatin, and fluoropyrimidines) or in monotherapy, starting with first-line therapy and in subsequent-
line treatment became standard of treatment for patients with advanced or metastatic colorectal cancer, 
which has led to a significant prolongation of life for this group of patients, with a median OS approaching 
3 years, in the hands of good oncologists and institutions promoting excellence. Selection of the indicated 
immunotherapy is based on predictive biomarkers such as RAS, BRAF, HER2 and primary tumor site 
(right or left colon) (16).
New immunotherapy with checkpoint inhibitors also plays an important role in a subset of patients 
at this stage of the disease, and the administration of this agent is primarily based on MSI-H and dMMR 
status. The percentage of patients with stage IV colorectal cancer with MSI-H (dMMR) is 3-5% (17).
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The activity of pembrolizumab was investigated in a phase II study involving 11 patients with dMMR 
and 21 patients with pMMR CRC with progressive metastatic disease. The ORR was 40% in the dMMR 
group and 0% in the pMMR. The PFS rate at week 20 was 78% in dMMR and 11% in pMMR. Median PFS 
and OS were not reached in the dMMR group while in the pMMR group it was 2.2 and 5 months, respec-
tively. This study demonstrated that MSI is a predictive marker for the efficacy of pembrolizumab (18). 
Nivolumab is another checkpoint inhibitor that has been tested alone or in combination with ipilimumab in 
the treatment of metastatic CRC. In the CheckMate-142 multi-cohort study, 72 patients with dMMR CRC 
were enrolled. The ORR for these patients was 31% and the disease control rate at week 12 was 69%. Median 
duration of response not reached. The PFS and OS rates at 12 months were 50% and 73%, respectively, with 
grade 3 and 4 adverse events of 20% (19). In another cohort of patients in the same study, nivolumab was 
tested in combination with ipilimumab for 119 patients with dMMR. ORR was 55%, disease control rate at 
week 12 was 80%, and PFS and OS rate at month 12 was 71% and 85%, respectively. Grade 3 and 4 side 
effects have been reported in 32% of patients (20). Based on these studies, pembrolizumab, nivolumab or 
nivolumab in combination with ipilimumab have become the recommended therapeutic options in subse-
quent-line treatment in guidlines for the treatment of metastatic dMMR colon cancer.
Conclusion
Modern checkpoint inhibitor immunotherapy has become a standard treatment for patients with 
advanced and metastatic gastrointestinal tumors expressing MSI-H or dMMR or PDL1 positive tumors. 
Although checkpoint inhibitors are generally well tolerated, serious immune side effects are reported in 
20-40% of patients, including skin, liver, kidney, gastrointestinal, lung, and endocrine toxicity, and it is 
very important for oncologists to know the potential toxicity of these drugs and patients should be aware 
and informed about possible occurrence of them.
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Neuroendorine tumors (NETs) represent a heterogeneous group of neoplasms that arise from cells in 
the diffuse neuroendocrine system. Although they can occur in multiple organs in the body, they are com-
mon int he gastrointestinal (GI) tract and pancreas, where they are thought to originate frome enterochro-
maffin cells oft he gut and islets of Langerhans cells in the pancreas. Although relatively rare, the incidence 
and prevalence of gastroenteropancreatic (GEP)-NETs (which is usual syntagme for all these tumore aris-
ing in GI system and pancreas) have been rising in most of the countries in the world.
Classification systems for GEP-NETs that are based on embryologic or anatomic origin, pathologic 
features, and clinical behavior have been developed and have been utilized to guide therapeutic strategies. 
Once a uniform disease, distinctions have been made among different subtypes of NETs, based on differ-
entiation and grade. In 2010 World Health Organization (WHO) presented an update to the classification 
of digestive neuroendocrine neoplasms. The most prominent feature was more precise and clearly mea-
sure of grading definition. Since than, there has been growing recognition that the 2010 WHO-grade cat-
egories do not reflect the heterogeneous phenotype of neuroendocrine neoplasms (Ki-67 >20% or mitotic 
indeks >20/10 high power-fields). Thus, the recently updated 2019 WHO criteria for GEP-NETs includes 
categories of well-differentiated grade 1, grade 2, and grade 3 NETs and maintains categories of poorly 
differentiated grade 3 neuroendocrine carcinomas. Historically, GEP-NETs have been classified according 
to their site of origin int he embryologic gut and, therefore, divided into foregut, midgut, and hindgut 
tumors. Today, due to molecular profiling further characterization ahs been made explaining some of 
clinical and therapeutic phenotypes. Molecular profiling has uncovered distinctions between poorly dif-
ferentiated NECs, NETs of the pancreas (pNETs) and those originating from other site sin the GI-tract. 
Poorly differentiated NECs harbor higher incidences of somatic mutations compared with the well-differ-
entiated cohorts. In well-differentiated NETs, when the genome si mutated, variants are most commonly 
identified in MEN1, genes involving mechanistic (or mammalian) target of rapamycin (mTOR) pathway, 
DAXX, and ATRX for pNETs, and CDKN1B in small bowel NETs. In pNETs, the presence of variants in 
DAXX and ATRX not only function as biomolecular markers but also, due to associated chromosomal 
instability are correlated with more advanced tumor stage and metastasis, reduced relapse-free survival, 
and decreased tumor-associated survival.
Therapeutic response has been correlated with anatomic site of origin. Specifically, response rate to 
cytotoxic agents have been significantly better in pNETs compared with well-differentiated NETs arising 
elsewhere. NETs are characterized by their ability to secrete peptide hormones that can lead to symptoms 
related to hormone excess. NETs are classified as functional tumors if patients clinically experience symp-
toms due to hormone hypersecretion by tumor and by that, syndrome is dependent on the type of hor-
mone produced. The best described is carcinoid syndrome with manifestations including diarrhea, flush-
ing, and bronchospasm, related to secretion of serotonin and other vasoactive peptides. Carcinoid syn-
drome is most common int he setting of disseminated disease, particularly with liver involvement. 
Subtypes of pNETs secreting hormones, including gastrin, insulin, vasoactive intestinal peptide, and other 
peptide hormones, have been identified and are associated with unique clinical manifestations. Today, 
there are multiple options available for the management of patients with advanced, metastatic GEP-NETs, 
including surgical resection, liver-directed therapies for patients with metastases predominantly in the 
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liver, and systemic therapy. The goals of therapy are to improve symptoms related to hormone hyperse-
cretion (in the case of functional tumors), slow disease progression and improve survival. Systemic ther-
apy options include – somatostatin analogues (SSAs), radiolabeled SSAs, molecularly targeted agents 
including everolimus and sunitinib and cytotoxic chemotherapy. SSAs, both lanreotide and octreotide, are 
the oldest systemic treatment options. Their activity is based on existence of somatostatin receptors (sst-r) 
on the surface of tumor cells. They can control symptoms but also slow the tumor growth, which was 
proved through clinical trials phase III (PROMID, ELECT, CLARINET). The same biologic feature is the 
basis for another, recent treatment option – radiolabeled SSA. NETTER-1 trial was phase III trial of 177-Lu-
DOTATATE for midgut metastatic NETs which showed median progression-free survival of 30 months 
and overal survival of 70 months. Another treatment option is vascular endothelial growth factor pathway 
(VEGF)-inhibitor (sunitinib, bevacizumab), and multiple clinical trials have evaluated the role of multi 
targeted tyrosine kinase inhibitors (TKIs) and monoclonal antibodies that target VEGF pathway. Rapamy-
cin inhibitors (mTOR-inhibitors) have been evaluated in different trials (RADIANT-2, RADIANT-3, RADI-
ANT-4), and it is evidence-based that in advanced nonfuctioning GI- and p-NETs as well as lung NETS, 
everolimus is superior to placebo regarding PFS (11 vs 3.9 months). Cytotoxic chemotherapies have been 
evaluated in advanced well-differentiated GEP-NETs. Activity was observed with alkylating agents, 
pNETs are more responsive than other tumors. Once, streptozocin-based therapy has been used but today 
temozolamide has more favorable administration schedule and toxitiy profile. Efficacy was analyzed in 
both retrospective and prospective trials. Poorly differentiated, grad 3 NEC are commonly treated with 
platinum-based chemotherapy regimens using an approach that is similar to treatment of small cell lung 
carcinoma. Finally, immunotherapy-based treatments are currently under investigation in GEP-NETs. 
There is limited activity of single-agent therapy. KEYNOTE-158 trial with pembrolizumab showed 
response rate of 3,7% in different NETs originating in the lung, GI-tract, or pancreas.
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Hepatocellular carcinoma (HCC), as the most common primary liver cancer, is among leading causes 
of cancer- related death worldwide. It occurs mainly in the setting of chronic inflammatory liver diseases, 
thus making the treatment extremely complex. Forty percent of patients with HCC are diagnosed in 
advanced stage and are candidates for systemic treatment. The approval of multikinase inhibitor sorafenib 
in 2007 was followed by many unsuccessful phase III trials assessing novel targeted therapies and locore-
gional therapies, such as radioembolization, that did not fulfill the primary overall survival (OS) end-
points. From 2016 to 2018, five new drugs (lenvatinib in the first- line and regorafenib, cabozantinib, ramu-
cirumab and immune checkpoint inhibitors (ICIs) in the second- line treatment) showed clinical efficacy 
and have been adopted by guidelines, but durable responses with monotherapy are rarely seen.
Liver, as the key immunologic organ, contains high proportion of various immune cell subtypes 
which play the role in HCC pathogenesis, making its phenotype immune evasive. Immune checkpoint 
inhibitors have shown modest efficacy as monotherapy in the first- and second- line treatment. Combina-
tion therapy for simultaneous inhibition of several immune checkpoints is currently being investigated. 
The CheckMate 040 trial (cohort 4) is investigating the combination of nivolumab and ipilimumab at vari-
ous doses and dose intervals. The Arm A regimen (four cycles of nivolumab at 1 mg/kg plus ipilimumab 
at 3 mg/kg every 3 weeks, followed by a 240-mg flat dose of nivolumab every 2 weeks) showed superior 
ORR (32%) and survival benefit (median OS 22.8 months) over two other investigational arms. A phase III 
HIMALAYA trial is currently investigating the combination of durvalumab and tremelimumab against 
durvalumab or sorafenib alone, based on superior response rate versus durvalumab alone in the phase I 
trial. In recent years, combinations of ICIs and molecular agents targeting angiogenesis have shown great 
promise, based on the role of proangiogenic factors released by tumor cells and vascular endothelial cells 
in creating an immune-inhibitory microenvironment. Based on the improvement in ORR shown in a phase 
II study, first- line treatment with an anti- PD-L1 antibody atezolizumab in combination with bevaci-
zumab was further investigated versus sorafenib in a phase III study (IMbrave150). The results were pre-
sented at ESMO Asia in 2019; median OS with the atezolizumab combination was not estimable (NE) 
compared to 13.2 months with sorafenib (HR 0.58; p = 0.0006). According to mRECIST criteria, the ORR 
was 33% versus 13% (p < 0.0001) in favor of combination. The authors concluded that atezolizumab plus 
bevacizumab has the potential to be a practice changing treatment in the first-line setting for patients with 
unresectable HCC. In a phase Ib study (Keynote- 524), lenvatinib in combination with pembrolizumab 
showed ORR of 53.3% which compared favorably with lenvatinib arm of registrational REFLECT trial 
(24.1%); disease control rate was 90.0%. The trial was expanded to the phase III (LEAP-002) in which this 
combination is being compared to lenvatinib alone. Many trials investigating combinations of immuno-
therapy and targeted agents (COSMIC- 312, SHR-1210-III-310, ORIENT-32) are ongoing, and it seems that 
more durable responses achieved by combining these agents may greatly change conventional treatment 
algorithms for HCC.
Patients with intermediate- stage HCC are at high risk for recurence after locoregional treatment, and 
so far no adjuvant therapy has been proved effective. Recently published results of TACTICS trial showed 
PFS benefit of transarterial chemoembolization (TACE) plus sorafenib versus TACE alone (25.2 vs 13.5 
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months; p=0.006), but no difference in overall survival. The promising treatment strategy for early- and 
intermediate- stage HCC is the combination of locoregional therapies and ICIs. Radiofrequency ablation 
(RFA), TACE and radiotherapy can trigger the release of neoantigens and enhance the effects of immuno-
therapy (abscopal effect). Microsatellite lesions typically undetectable on imaging are the main cause of 
recurrence after curative therapy for HCC. When release of tumor antigen is induced by TACE or RFA, 
subsequent administration of an anti-PD-1 antibody may inhibit intrahepatic micrometastases. Several 
phase III trials investigating ICIs in the adjuvant treatment, alone or in combination with other strategies, 
such as antiangiogenic treatment or TACE (CheckMate 9DX, Keynote -937, EMERALD-2, EMERALD-1) 
are ongoing.
Biliary tract cancers (BTC) are poor prognosis malignancies with limited treatment options. Cape-
citabine remains the standard of care in the adjuvant setting. Several trials (ACTICCA-1, AdBTC-1, 
JCOG1202, ASCOT) are currently investigating whether there is added clinical benefit of intensification of 
chemotherapy, antiangiogenic treatment or immunotherapy in resected BTC. Treatment of advanced dis-
ease is still limited to first-line cisplatin and gemcitabine chemotherapy. Recent global efforts in genomic 
profiling and molecular subtyping of BTCs have uncovered a wealth of genomic aberrations which may 
carry prognostic significance and/or predict response to treatment, and several targeted agents (IDH 
inhibitors, FGFR inhibitors, BRAF inhibitors, anti-HER2 directed therapies, NTRK- fusion directed agents) 
have shown promising results in clinical trials. Based on the results of a basket trial, in 2017 FDA approved 
ICIs for patients with MSI/dMMR tumors (including BTC) after progression on standard treatment options. 
Given the promising responses to immunotherapy thus far, there is a strong rationale for testing the com-
bined checkpoint inhibition and combining ICIs with chemotherapy, as well as the adoptive immuno-
therapy. The uptake of comprehensive genomic profiling for patients with BTCs and the expansion of 
basket trials to include these patients are growing. However, a deeper understanding of potential resis-
tance mechanisms and the complex crosstalk between molecular pathways is growing and combination 
strategies targeting more than one pathway are being proposed. In order to benefit from tailored therapy, 
genomic testing for all patients with BTC should be considered and liquid biopsy may be the most conve-
nient way to implement this.
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Although there is a steady decline in gastric cancer (GC) incidence in the past few decades, it is still 
the fifth most frequently diagnosed cancer and the third leading cause of cancer death in the word. Sur-
vival is highly associate with the stage of the disease at diagnosis. Therefore, the optimisation of treatment 
of localised and loco-regional disease is of paramount importance.
As the recurrence rate after surgery is as high as 40-50% during the first 3 years, numerous studies 
have examined the optimal multimodal approach of the following strategies: postoperative chemotherapy 
(EORTC+ICCG, ACTS-GC, GIRC, CLASSIC, JACCRO GC-7), postoperative chemo-radiotherapy (SWOG/
INT 0116, ARTIST), perioperative chemotherapy (MAGIC, FNCLL/FFCD, FLOT4-AIO), neoadjuvant che-
motherapy (EORTC 40954), neoadjuvant chemo-radiotherapy (POET).
In Western countries according to the both, NCCN and ESMO guidelines, perioperative chemother-
apy is recommended for patients with cT2 or grater non-metastatic disease. In MAGIC trail perioperative 
ECF (epirubicin, cisplatin, 5-fluorouracil) improved 5-years overall survival (OS) from 23% with surgery 
alone to 36%. Similarly, in FNCLL/FFCD trial perioperative CF (cisplatin, fluorouracil) improved 5-years 
survival from 19% with surgery alone to 34%. Most recently, FLOT4 trial compared ECF to FLOT (docetaxel, 
oxaliplatin, leucovorin, 5-fluorouracil) regimen in perioperative setting. After median follow-up of 43 
months median OS of patients treated with FLOT was 50 months, and those treated with ECF 35 months 
(p=0.012). The estimated 3-years OS gain was 9%. Thus, FLOT become the new standard of care.
In patients with ≥ pT2 or pN+ who have undergone surgery without preoperative chemotherapy 
postoperative chemo-radiotherapy is recommended in case of less than a D2 dissection or R+ margin. If D2 
dissection was performed with R0 margins adjuvant chemotherapy is preferable. Although adjuvant 
chemo-radiotherapy improved 3-years OS in comparison with surgery alone (p=0.005) in the SWOG/INT 
016 trial, the study was criticized frequently for inadequate lymphadenectomy in majority of included 
patients. In the ARTIST trial (only D2 dissection allowed) adjuvant chemo-radiotherapy improved 3-years 
disease-free survival (DFS) significantly (p=0.04) only in patients with positive lymph nodes but not in the 
whole cohort of patients. For patients treated with preoperative chemotherapy the addition of postopera-
tive chemo-radiotherapy did not show any benefit in OS and DFS in comparison to perioperative chemo-
therapy in the CRITICS trial. Two trials, TOPGEAR and CRITICS-II, that are currently enrolling patients, 
investigate neoadjuvant chemo-radiotherapy.
Adjuvant chemotherapy resulted in improved OS and DFS in the CLASSIC and ACTS-GC studies 
performed in the Asian population but the applicability of the results of this studies to the Western popu-
lation is somewhat uncertain. One meta-analysis confirmed a 6% absolute benefit for 5-fluorouracil-based 
chemotherapy compared with surgery alone, while a recent one concluded that adjuvant oxaliplatin-fluo-
ropyrimidine was the most promising regimen after curative resection.
Two randomised, phase III trials compared perioperative and adjuvant chemotherapy in Asian popu-
lation. In the PRODIGY trial neoadjuvant chemotherapy with docetaxel, oxaliplatin and S-1 followed by 
surgery and adjuvant S-1 improved 3-years progression-free survival (PFS) in comparison to surgery and 
adjuvant S-1 (p=0.023). The RESOLVE trial compared perioperative oxaliplatin and S-1 (SOX) with postop-
erative SOX or postoperative oxaliplatin and capacitabine (XELOX). Perioperative SOX improved 3-years 
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DFS compared with XELOX (p=0.045). Postoperative SOX was non-inferior to postoperative XELOX 
(p=0.162).
However, majority of previously mentioned trials investigated GC as one entity but in recent years 
we have become aware that GC is a very heterogeneous disease and that will influence the choice of treat-
ment in the future. In post-hoc analysis of the MAGIC trail patients with high microsatellite instability had 
better survival when treated with surgery alone than chemotherapy. In the CLASSIC trial there was also 
no survival benefit of adjuvant chemotherapy in the high microsatellite instability group. Furthermore, 
there are several active clinical trials examining the role of immunotherapy in the perioperative and adju-
vant treatment (Checkmate 577, KEYNOTE 585, ATTRACTION-05, VESTIGE) as well as the role of tar-
geted therapy in the perioperative treatment of GC (PETRARCA, INNOVATION, RAMSES).
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Approximately 570 000 cases of cervical cancer and 311 000 deaths from the disease occurred in 2018. 
Cervical cancer was the fourth most common cancer in women.
Cervical cancer continues to be a major public health problem affecting middle-aged women, particu-
larly in less-resourced countries. The global scale-up of HPV vaccination and HPV-based screening has 
potential to make cervical cancer a rare disease in the decades to come.
The implementation of primary and secondary prevention can make cervical cancer occurrence and 
death largely avoidable. Bivalent and quadrivalent HPV vaccines containing HPV16 and HPV18 antigens 
protect with high efficacy against infection and precancerous cervical lesions. Both types jointly cause 
70–75% of all cervical cancers and 40–60% of its precursors.
By adding the two screening tests and the treatment of precancerous cervical lesions, cervical cancer 
cases will drop by 97% and 72 million cervical cancer cases will be averted over the next century. Further-
more, 62 million cervical cancer deaths will be averted.
Suggested therapy for FIGO 2018 stages IA to IB2 is surgical approach 
Therapy for FIGO 2018 stages IB3 to IVA consist of multimodality therapy concurrent chemoradia-
tion (weekly cisplatin) comprising external-beam radiation therapy with systemic chemotherapy (CCRT) 
then intracavitary brachytherapy.
Immune checkpoint blockade with ipilimumab, combined with radiation therapy, is tolerable and 
effective in patients with node-positive, stage Ib2 to IVA cervical cancer, according to results of a prospec-
tive phase I study. In the phase I study, investigators evaluated sequential ipilimumab after chemoradio-
therapy as a curative-intent treatment of patients with node-positive cervical cancer. Among patients who 
received at least 2 cycles of treatment, the 12-month OS rate was 90% and the PFS rate was 81%.
A new study, evaluating atezolizumab before and/or with chemoradiotherapy in this patient popula-
tion has been launched to further evaluate the benefit of immune checkpoint blockade.
Phase II trial reported in the Journal of Clinical Oncology, da Costa et al found that neoadjuvant cis-
platin/gemcitabine followed by standard chemoradiation therapy with cisplatin did not improve out-
comes vs chemoradiation therapy alone in locally advanced cervical cancer. Outcomes were better with 
standard chemoradiation therapy alone.
Concurrent RT with platinum-based doublet chemotherapy significantly improved the OS and PFS 
buth with more frequent grade 3 or 4 side effects in the polychemotherapy arm.
Study of Yavas on 109 patient showed that adjuvant chemotherapy (paclitaxel and carboplatin) after 
CRT in patients with LACC significantly improved both disease-free survival and overall survival (93.5% 
and 95.7% and 69.8% and 82.5 % for the CRT + chemotherapy and CRT groups) without increasing unman-
ageable toxicity. Future larger prospective trials are warranted to verify these findings.
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Management of FIGO 2018 stages IVB and recurrent disease: From the GOG-0204 trial, paclitaxel 
plus cisplatin emerged as the palliative standard. The Japanese Clinical Oncology Group demonstrated 
significant noninferiority with substitution of carboplatin (area under the curve 5) for cisplatin in the 
phase III clinical trial JCOG0505 but noted that carboplatin was associated with shorter overall survival 
among cisplatin-naïve patients.
GOG-0240, a phase III open-label randomized study of chemotherapy doublets with and without 
bevacizumab every 21 days until progression. The triplet regimen is now standard of care.
Active Clinical Trials:
Evidence for activity of checkpoint inhibitors is accumulating.
KEYNOTE-158 phase II study of pembrolizumab in 77 pt demonstrated an objective response rate of 
14.3%. FDA granted pembrolizumab as a second-line agent.
Investigators have launched the confirmatory, front- line, placebo-controlled phase III randomized 
KEYNOTE- 826 trial studying platinum-based chemotherapy plus optional bevacizumab with and with-
out pembrolizumab, as well as the frontline phase III randomized BEATcc trial evaluating triplet therapy 
with cisplatin, paclitaxel, and bevacizumab with or without atezolizumab.
A second-line, phase III randomized trial, EMPOWER CERVICAL-1/GOG 3016, activated in 2017, is 
comparing the anti–PD-1 agent cemiplimab to physician’s choice of chemotherapy.
Nivolumab was assessed in patients with recurrent or metastatic cervical cancer in the phase I/II 
CheckMate 358 trial. Patients received nivolumab 240 mg every 2 weeks the median duration of treatment 
was 5.6 months in the cervical cancer cohort. The ORR was 26.3% (95% CI, 9.1-51.2) in the cervical cancer 
arm. At a median follow-up of 19.2 months, the median duration of response (DOR) was not reached. The 
median PFS in the cervical cancer group was 5.1 months with a median OS of 21.9 months
CheckMate 358 is an ongoing phase I/II study of nivolumab and ipilimumab in patients with recur-
rent and metastatic cervical cancer. Results suggest clinical benefit from two regimens of Nivo + Ipi in pts 
with R/M cervical cancer regardless of PD-L1 status.
LN-145, a tumor-infiltrating lymphocyte (TIL) therapy, demonstrated promising response rates and 
an acceptable safety profile in patients with recurrent, metastatic, or persistent cervical cancer in the phase 
II study. Results presented at the 2019 ASCO for 27 patients reported an objective response rate of 44%. Of 
those who responded, 11% were complete responders and 33% were partial responders. Another 40% of 
patients had stable disease as their best response. It’s worth mentioning that the follow-up for this study 
was very short; median follow-up was 7.4 months, and the median DOR had not reached.
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S19 - OPTIMAL TREATMENT OF ENDOMETRIAL CANCER
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Endometrial cancer is the most common gynecological cancer and primarily affects postmenopausal 
women. The incidence is rising due to increased obesity and aging of the population. In Croatia, endome-
trial cancer is the fourth most common cancer in woman with 717 new cases and 113 deaths in 2017. Sur-
gery is the primary treatment in patients with endometrial cancer. Standard surgical procedure should 
involve hysterectomy with bilateral adnexectomy with or without lymphadenectomy. The role of lymph-
adenectomy in early stage of endometrial cancer is unclear.
Depending on findings from final pathological analysis of the uterus and other surgical specimens, 
patients can be stratified into risk categories. Adjuvant treatment is currently recommended based on a 
patient’s individual risk (low-, intermediate- and high- risk) comprised of a combination of clinical finding 
(age) and pathological findings (FIGO stage, tumor type, grade and the presence of lymphovascular space 
invasion). Adjuvant radiotherapy can be delivered through vaginal brachytherapy (VBT) or external beam 
radiotherapy (EBRT) with or without VBT. The decision, which therapy approach should be done, depends 
on the clinical and pathological risk factors.
In patients with metastatic, recurrent or high grade disease, chemotherapy is recommended. The 
preferred chemotherapy regimen is paclitaxel/ carboplatin.
The extensive molecular-genetic characterization of endometrial cancer by the Cancer Genome Atlas 
Grup (TCGA) is done and four different molecular subclasses were identified: POLE-mutant, MSI sub-
class, copy-number high and copy-number low subclass. In POLE-mutant endometrial cancer, an increased 
antitumor response by peritumoral and tumor-infiltrating CD8+ lymphocytes has been reported and 
patients in that group have an excellent prognosis with only occasional relapse, independent of receiving 
adjuvant treatment. Microsatellite unstable (MSI) subclass shows a similar increase in tumor-infiltrating 
lymphocytes, however, it is associated with negative prognostic factors such as higher histological grade, 
presence of LVSI, older age and advanced stage of disease (FIGO III/IV).Copy-number low subclass (non-
specific molecular profile) are characterised by low mutational burden and it contains a heterogeneous of 
tumors. Copy-number high subclass (TP53 mutation positive) is associated with unfavorable overall and 
prognostic free survival. In this subgroup, amplification of the human epidermal growth factor receptor 2 
(HER-2) and homologous recombination deficiency (HRd) are frequent.
It is assumed that in early stage patients with POLE subgroup and without other risk factors, adju-
vant therapy could be omitted. In patients with MSI and copy-number low subclasses, vaginal brachy-
therapy should be recommended, and in patients with copy-number high subclass adjuvant treatment by 
EBRT is justified.
The ongoing PORTEC4a trial will determine value of integrating molecular parameters in adjuvant 
treatment.
Standard initial adjuvant therapy for advanced or recurrent endometrial cancer is paclitaxel plus 
carboplatin. Treatment options for advanced or recurrent disease after initial platinum-taxane therapy are 
being investigated.
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Expression of estrogen and progesterone receptor are common in endometrial cancer and it is related 
to lower grade tumors. Targeting the endocrine receptors by hormonal therapy can provide durable 
response in patients with grade 1 metastatic endometrial cancer, especially with lung- or oligo-metastatic.
According to the KEYNOTE-028 study, in a subset of 24 patients with advanced endometrial cancer 
characterised with programmed death ligand 1 (PD-L1) positive tumors, pembrolizumab is associated 
with durable antitumor responses (3 partial response, 3 stable disease). In a phase 2 study of lenvatinib 
monotherapy in patients with advanced, previously treated endometrial cancer, 14% had an objective 
response and median PFI was 5.4 months.
In the KEYNOTE-146/Study 111 trial, the combination of pembrolizumab and lenvatinib is associated 
with good response (38.8%) in patients with previously treated metastatic endometrial cancer, and the 
median duration of response was not reached at the time of cut-off. According to this trial, FDA approved 
the combination of pembrolizumab and lenvatinib for the treatment of patients with advanced endome-
trial carcinoma that is not MSI-H or mismatch repair deficient (dMMR), who have progression following 
prior systemic therapy and not candidates for curative surgery or radiation.
Some other trials evaluated the role of the molecular risk factors and if any of these molecular risk 
factors can be used for guide of the treatment. HER-2/neu amplification are frequently found in serous 
endometrial cancer. In a recent study, the combination of trastuzumab with carboplatin/paclitaxel in those 
patients resulted in a prolonged PFS of 13 months compared to 8 months in carboplatin/paclitaxel group 
(in patients undergoing primary treatment, the median PFS improved from 9.3 to 17.9 months).
Antiangiogenic therapy have some activity in endometrial cancer. Bevacizumab was shown to have 
a 13.5 % response rate in patients with persistent or recurrent endometrial cancer. In the GOG 86P trial, the 
addition of bevacizumab to first line paclitaxel/carboplatin chemotherapy did not improve PFS, but it 
increased OS. And the MITO END-2 trial failed to demonstrate a significant increase in PFS.
The PI3K-AKT-mTOR pathway is altered in over 80% endometrial cancers Promising results have 
been described for combined treatment with PI3K inhibition and endocrine therapy (the combination of 
everolimus and letrozole).
Some patients, especially in the TP53-mutated or serous-like subclass, have homologous recombina-
tion deficiency (HRd). In those patients, PARP inhibitors have been investigated.
Endometrial cancer is recognized as several biologically different cancers. Current practice is to 
decide which adjuvant therapy or therapies for advanced/recurrence disease select according to standard 
histopathological risk factors. However, with increasing knowledge of the molecular alterations of cancer, 
their prognostic value and possible therapeutic options, it is expected that the molecular characteristics 
will be taken into account prior deciding on the recommended therapy.
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Case report: Endometrial cancer is the most common cancer of the female genital tract. Lung metastases 
from endometrial cancer are 20% more often than from any other gynecologic cancer. We report a case of a 
73-year-old women with endometrial cancer diagnosed at stage IIB according to the International Federation 
of Gynecology and Obstetrics (FIGO), 2008 classification of endometrial cancer. The patient underwent 
abdominal total hysterectomy, bilateral salpingo-oophorectomy, pelvic lymphadenectomy and omentec-
tomy. Microscopically, it was good differentiated endometrial cancer which infiltrated more than half thick-
ness of the uterine wall and cervical stroma. Estrogen and progesterone receptors were expressed in more 
then 70% of cancer cells. Left and right pelvic lymph nodes showed no evidence of malignancy in 15 exam-
ined nodes. Multidisciplinary team decision was to perform adjuvant radiotherapy to the pelvis. Adjuvant 
therapy recommendations for early-stage disease are based on high-risk prognostic factors predictive of 
increased risk of recurrence, including older age, histologic type, histologic grade, deep myometrial inva-
sion, lymphovascular space invasion and involvement of lower uterine segment or cervix. Following this 
decision, 50Gy/25 fraction of pelvic external beam radiotherapy and 21Gy/3 fraction HDR Ir-192 brachyra-
diotherapy of vaginall cuff were administrated. During regular clinical monitoring, in March 2017, the patient 
visited to a pulmonologist due to expectorated cough and weight loss. Morphologic evaluation with multi-
slice computed tomography (MSCT) of chest showed multiple lung metastases. Lung biopsy was performed 
and patological findings confirmed good differenciated, hormone positive metastasis from endometrial can-
cer. Hormonal therapy with megestrol-acetate (Megace 160 mg daily) was administered according to Multi-
disciplinary team decision. At the beginning of treatment patient performans status was good and laboratory 
tests were within normal ranges. After two months of therapy patient had good quality of life, without 
therapy toxicity. The best respond to hormonal therapy was partial response. Morphologic evaluation in 
November 2018 showed progression of disease due to the growth od existing metastases and occurrence of 
a new lung metastases. Patient was treated with 2nd line hormonal therapy, aromatase inhibitor (Letrozol 2,5 
mg daily). Stable disease persisted until August 2019 when MSCT showed further disease progression in 
lung. Chemotherapy, TC protocol (paclitaxel and carboplatina) every three weeks were started. On the third 
day after the first cycle of chemotherapy the patient developed weakness and joint pain grade 3, dizziness, 
loss of appetite and uroinfection. Symptomatic-supportive treatment was given and general condition of 
patient recovered within a few days. Chemotherapy was continued in a reduced dose. Morphologic evalua-
tion performed after five cycles of chemotherapy showed mild regression of disease. The treatment plain is 
to continue to administer chemotherapy until disease progression or unacceptable toxicity. Patient is still in 
good general condition. She developed chemotherapy-induced peripheral neuropathy grade 2 and alopecia. 
Treatment of metastatic endometrial cancer requires an individualized approach, based on patients age, 
performans status, comorbidities, characteristics of tumor, previously administered therapy and the time 
from adjuvant treatment to disease progression.
REFERENCES:
1.  Waldmann A, Eisemann N, Katalinic A. Epidemiology of Malignant Cervical, Corpus Uteri and Ovarian Tumors - Cur-
rent Data and Epidemiological Trends. Geburtshilfe Frauenheilkd. 2013;73(2):123-9.
2.  The National Comprehensive Cancer Network. Guidlines version 4. 2019. Uterine neoplasms
45
Lib Oncol. 2020;48(Suppl 1):3–69
MELANOMA
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In the last decade, we are witnesses of head – spinning progress in melanoma therapy, providing 
prolonged clinical responses and benefit to melanoma patients, even cure.
Targeted therapies have become the standard of care in BRAF V600-positive metastatic melanoma, 
and, just recently, in the adjuvant treatment of high-risk BRAF V600-positive melanoma.
Furthermore, recent results of neoadjuvant trials show high efficacy, and numerous studies of tar-
geted therapies in combination with immunotherapy, either concomitantly or sequentially, are ongoing, 
with encouraging initial results. Targeted therapy can be a therapeutic option only in BRAF V600 mutated 
disease, which is mutated in approximately 50% of melanoma patients.
Targeted therapy in melanoma nowadays comprises of dual inhibition of MAPK – signaling path-
way, by inhibiting BRAF-protein and MEK-protein in patients with BRAF-mutated disease. A combina-
tion of the two inhibitors of the same pathway results in a better and prolonged response due to overcom-
ing resistance to therapy.
The final results of coBRIM phase III trial at 5 years of follow-up showed that the combination regi-
men maintained an advantage in both overall survival (OS) and objective response rate (ORR) compared 
with vemurafenib alone.
Cobimetinib&vemurafenib improved OS and progression-free survival (PFS) by roughly 5 months 
compared with vemurafenib alone. The 5-years OS rates were 30.8% vs. 26.3%, respectively. The median 
OS was 22.5 months (95% CI, 20.3-28.8) with the combination compared with 17.4 months (95% CI, 14.5-
19.8) for the monotherapy. The 5-year PFS rates were 14% versus 10%, respectively. The median PFS at 5 
years was 12.6 months (95% CI, 9.5-14.8) with cobimetinib&vemurafenib versus 7.2 months (95% CI, 5.6-
7.5) with vemurafenib alone.
The pooled extended-survival data from two trials (COMBI-d and COMBI-v) involving previously 
untreated patients who had received BRAF-inhibitor dabrafenib with MEK-inhibitor trametinib after the 
median duration of follow-up 22 months (range, 0 to 76) showed PFS rates 21% (95% confidence interval [CI], 
17 to 24) at 4 years and 19% (95% CI, 15 to 22) at 5 years. The overall survival rates were 37% (95% CI, 33 to 
42) at 4 years and 34% (95% CI, 30 to 38) at 5 years. In multivariate analysis, several baseline factors (e.g., 
performance status, age, sex, number of organ sites with metastasis, and LDH level) were significantly asso-
ciated with both PFS and OS. Complete response occurred in 109 patients (19%) and was associated with an 
improved long-term outcome, with an overall survival rate of 71% (95% CI, 62 to 79) at 5 years.
Targeted therapies in melanoma are effective even in patients with brain metastases, as shown by the 
results of COMBI-MB clinical study, although the median duration of response was relatively short. A 
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recent meta-analysis from 2019 aimed to better clarify the activity and efficacy of combination targeted 
therapies (TT), monotargeted TT (monoTT), combination immunotherapy (CMI), monoimmunotherapy 
(MI), and combination with radiotherapy (CRI) in patients with melanoma brain metastases. A total of 15 
trials were included in the meta-analysis, with 1132 patients analyzed. CMI demonstrated a statistically 
significant better OS compared with MI (P =.03, P =.05, and P =.03, respectively, at 6 months, 18 months, 
and 24 months) and combination TT (P =.04 and P =.03, respectively, at 18 months and 24 months). CMI 
demonstrated a statistically significant better PFS compared with combination TT (P <.001 at 12 months 
and 18 months), MI (P =.02, P <.02, and P =.05, respectively, at 6 months, 12 months, and 18 months), and 
mono TT (P <.001 at 6 months, 12 months, and 18 months). The intracranial ORR was higher with CMI 
compared with mono TT (P <.001) and MI (P <.001), whereas there was no difference between CMI and 
combination TT. The results suggested that CMI increases long-term PFS and OS compared with MI and 
combination TT. However, combination TT and CMI are associated with a similar intracranial response 
rate. The role of systemic therapy in combination with radiotherapy remains to be better elucidated.
Based on the results of COMBI-AD phase 3 clinical study, adjuvant targeted therapy of high-risk 
melanoma patients has become the standard of care of BRAF V600 – mutated disease. Longer follow-up 
confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected 
BRAF V600-mutant stage III melanoma. At median follow-up of 44 months (dabrafenib plus trametinib) 
and 42 months (placebo), 3- and 4-year RFS rates were 59% (95% CI, 55% to 64%) and 54% (95% CI, 49% to 
59%) in the dabrafenib plus trametinib arm and 40% (95% CI, 35% to 45%) and 38% (95% CI, 34% to 44%) 
in the placebo arm, respectively (HR, 0.49; 95% CI, 0.40 to 0.59). Distant metastasis-free survival also 
favored dabrafenib plus trametinib (HR, 0.53; 95% CI, 0.42 to 0.67). The estimated cure rate was 54% (95% 
CI, 49% to 59%) in the dabrafenib plus trametinib arm compared with 37% (95% CI, 32% to 42%) in the 
placebo arm. Subgroup analysis of RFS demonstrated similar treatment benefits regardless of baseline fac-
tors, including disease stage, nodal metastatic burden, and ulceration.
The „hot topic“ in melanoma research in the last several years is neoadjuvant therapy. A number of 
neoadjuvant targeted and immunotherapy studies have been completed in melanoma to date and have 
yielded promising clinical activity. The recent pooled analysis from 2019, showed that in the neoadjuvant 
setting, IT and TT are active regimens in resectable clinical stage III melanoma patients and are associated 
with high pCR rate. The ability to achieve pCR correlates with improved RFS, however, more so in patients 
receiving immunotherapy. For patients with pCR after neoadjuvant therapy, 7% have recurred, 0/51 (0%) 
after IT, 7/17 (41%) after TT. For those without pCR, 34% have recurred, 18/82 (22%) after IT and 19/27 (70%) 
after TT. Twelve-month RFS was improved in those with pCR vs without pCR (95% vs 62%, p < 0.001), 
including in those with IT (100% vs 72%, p < 0.001) and TT (88% vs 43%, p < 0.001). Sixteen (9%) patients 
have died, including two who had a pCR, both from TT. Given these encouraging results, a number of stud-
ies with other molecularly targeted and immunotherapeutic agents and their combinations are ongoing in 
the neoadjuvant setting; long-term outcome data are eagerly awaited. Such studies also provide access to 
biospecimens before and during therapy, allowing for the conduct of biomarker and mechanistic studies 
that may have a significant impact in guiding adjuvant therapy choices and drug development.
Due to the potential of BRAF- and MEK- inhibitors for immunomodulation, and potential immunos-
timulation, i.e., synergy with immunotherapy, numerous clinical studies are ongoing, exploring the poten-
tial of combining targeted therapy with immunotherapy. Emerging evidence indicates that targeted therapy 
synergizes the function of immune cells and the immune microenvironment endorsing the rationale of com-
binatorial therapy. The potential molecular mechanisms included: (1) promotion of melanocyte differentia-
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tion antigens expression; (2) agitation of T-cell infiltration into tumor microenvironment; and (3) abrogation 
of the immunosuppressive tumor microenvironment. Preclinical and clinical studies also proved the advan-
tage of synergizing oncogene-targeted therapy and immunotherapy. However, the concomitant use of tar-
geted therapy with immunotherapy has generated serious adverse events (AEs). It is also important to inves-
tigate proper sequencing of combination targeted therapy (BRAF&MEK inhibitors) with immune checkpoint 
inhibitors (anti-CTLA or anti-PD-1/PD-L1 antibody), due to the fact that patients treated with targeted ther-
apy may display distinct immune-compatibility: either be more sensitive or be more tolerant. Apart from 
toxicity, proper sequencing and timing of therapies should be considered and accessed when the combinato-
rial regimens are designed. Specific biomarkers or predictors of response and AEs may be important to 
achieve personalized treatment. Although MEK-inhibitors can create favorable tumor microenvironment, 
they may impair the function of antigen-specific T-cells by inhibiting physiological MAPK pathway. There-
fore, how to enhance synergy of combinatorial regimens through avoiding small molecular inhibitors 
induced T-cell toxicity is another challenge. In order to minimize the toxicity of combination targeted ther-
apy with immunotherapy, novel drugs, and innovative combinatorial strategies need to be further explored. 
Better understanding the complex interference between targeted therapy and immunotherapy will be help-
ful in developing more effective agents and to design better combinatorial regimens.
It is highly desired to identify and characterize the biomarkers that predict response or adverse events 
with targeted or immunotherapeutic drugs. Initially, we need to determine which subpopulation of 
patients are likely to benefit from targeted therapy or immunotherapy, in other words, what biomarkers 
can be used to predict the effect of drugs before treatment.
In 2019, research in the melanoma field continued its rapid pace of advancement. In the last decade, 
researchers have made remarkable progress in clinical, translational and basic research, improving 
patients’ outcomes, and later on, focusing on expanding our understanding of treatment resistance, of 
identifying new treatment targets, but also on improving melanoma detection and prevention. However, 
there are still some unmet needs in melanoma field (especially uveal melanoma, mucosal melanoma, 
patients with adverse prognostic factors---), and we eagerly await future headways.
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Effective immunotherapy in routine clinical application against human solid tumors started in the 
last decade. This immunotherapy is based on the so-called immune checkpoint blockade. This means that 
humanized monoclonal antibodies against inhibitory checkpoint cell membrane proteins (“inhibitory 
receptor molecules“) on CD8+ T cells or their ligands on antigen presenting cells (APC) or tumor cells 
block inhibitory signals and thus enable nonspecific T cell activation and clonal proliferation. In this way 
nonspecifically activated T cells recognize and eliminate autologous tumor cells in oncological patients. 
The curiosity of this approach is that these monoclonal antibodies are not directed against tumor cells but 
against molecules on (immune) cells which physiologically regulate T cell activity. The discovery and suc-
cessful clinical application of such checkpoint inhibitors culminated in the award of the Nobel Prize in 
Physiology or Medicine in 2018. This anti-cancer immunotherapy approach was first applied in patients 
having metastatic melanoma. Later it was found that it can be succesfully applied to patients having sev-
eral other metastatic types of cancers, for example non-small cell lung cancer, kidney cancer and urothelial 
carcinoma. Remarkcably, some 30 to 40% of treated patients have probably been cured, which was not the 
case before. The question of why in the case of certain types of cancers only a percentage of treated patients 
responds while in the case of many other types of cancer there is no effect whatsoever remains unan-
swered. This underscores the need to identify predictable parameters and mechanisms of primary and 
secondary resistance to immune checkpoint blockade. Some of the causes for this might lie in tumor micro-
environment cell composition and even in gut microbiota composition (1-8). In view of the fact that for 
several years now immune checkpoint blockade has been standard therapy for patients having metastatic 
cutaneous melanoma as well as adjuvant therapy in patients with high-risk primary melanoma (stage 
IIB/C) or completely resected lymph node (LN) metastases (stage III) (9, 10) and that therapeutic responses 
are obtained only in part of the patients treated, the main focus of this topic is to present other possible 
immunotherapeutic approaches which could be exploited, such as autologous cellular therapy with adop-
tive T cell transfer raised in vitro and expanded with cytokine interleukin-2 (rIL-2) from tumor infiltrating 
lymphocytes (TILs) or with chimeric antigen receptor (CAR) T cell (11-14). The CAR is an artificial trans-
membrane receptor which has an antibody fragment that targets cell surface antigens on cancer cells, and 
an intracellular domain that activates the CD3 signalling pathway once antigen binding has occurred. 
Cytokine therapy with rIL-2 might also find a broader application due to the novel formulation of rIL-2 
which is bound to polyethylene glycol (PEG) chains. This novel formulation of rIL-2 has a longer half-life 
and much better tolerability than rIL-2 (aldesleukin), which was previously used and approved for the 
treatment of metastatic renal cell carcinoma and metastatic melanoma and which had to be applied intra-
venously at a very high-dose levels, which resulted in significant and dose-limiting toxicities (2, 15). When 
considering immunotherapeutic approaches to melanoma, it seems that there are no registered clinical 
studies based on the use of antibody drug conjugates and on bispecific T cell engagers (BiTEs) (11-14). 
Oncolytic viruses (T-VEC, Imlygic) have also been approved as a form of local therapy for melanoma 
patients having unresectable cutaneous, subcutaneous, and nodal melanoma lesions. Clinical studies com-
bining T-VEC therapy with other forms of therapy are also underway (16,17).
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Immunotherapy nowadays represent a new approach in standard of care in the treatment of meta-
static melanoma. The survival of patients with metastatic melanoma is dramatically enlarged with immu-
notherapy. The positive results in adjuvant studies have recently been published too. The improvement in 
survival is also observed for other types of cancer, so number of patients treated with immunotherapy is 
increasing.
Immunotherapy in metastatic or unresectable melanoma include two immunomodulating approaches: 
anti-PD-1 drugs (nivolumab and pembrolizumab) and anti-CTLA-4 antibody (ipilimumab). The anti-PD-1 
antibodies have a different toxicity profile to ipilimumab with fewer high grade events.
The side effects of checkpoint inhibitors are uniformly termed as immune-related adverse events 
(irAEs). These include endocrine, dermatologic, gastrointestinal (GI) toxicities, but all organs can be 
affected, though other inflammatory events are less common. All these adverse events have an autoim-
mune etiology and can appear at any time during the treatment and even one year after stopping the 
immunotherapy. IrAEs therefore need careful monitoring, follow-up and management. Several guidelines 
and algorithms have been developed and published for the management of irAEs. With appropriate treat-
ment, applied on time, irAEs toxicities are usually reversible, but if they are not recognized early enough 
they can become severe and even life-threatening. Before treatment initiation with immunotherapy, 
patients should be informed about the potential AEs of immunotherapy and warned to report all cases 
directly to the treating team, physician or nurse.
Inhibitors of PD-1 interfere with normal mechanisms of immune tolerance while inhibiting tumor 
immune escape. The increase in immune activation caused by these inhibitors in normal tissues may be 
responsible for various types of significant irAEs, which include endocrine, skin, pulmonary, gastrointes-
tinal, hepatic, renal, neurologic, cardiac, and hematologic autoimmune diseases. The meta analysis that 
included forty-six studies with 12,808 patients different cancer types treated with the PD-1 signaling inhib-
itors, showed the overall incidence of irAEs 26.82% (95% CI, 21.73–32.61; I2, 92.80) in any grade and 6.10% 
(95% CI, 4.85–7.64; I2, 52.00) in severe grade, respectively. The incidence of death due to irAEs was around 
0.17%. The development of irAEs was unrelated to the dose of anti-PD-1 agents.
The optimal management of irAEs include the early recognition and the appropriately-timed use of 
immunosuppressive agents: steroids or anti-TNF-α, based on the severity of the event.
Hepatitis can occur in 5-10 % of patients treated with immunotherapy. All patients should have 
serum transaminases and bilirubin measured before every cycle of treatment. Hepatitis is usually asymp-
tomatic and can be detected on routine blood monitoring. If hepatitis is suspected viral hepatitis and con-
comitant drug administration should be excluded. Liver biopsy can be considered in severe reactions. If 
grade 2 transaminase or total bilirubin elevation detected, immunotherapy should be withheld and trans-
aminases and bilirubin measured twice weekly. If it last longer than 1–2 weeks corticosteroids at a dose of 
1 mg/kg/day should be started. If no improvement occurs, or in case of grade 3 or 4 irAEs corticosteroid 
dose should be increased to 2 mg/kg/day and immunotherapy permanently discontinued. If there is no 
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response to corticosteroids within 2–3 days, mycophenolate mofetil should be added at 1000 mg twice 
daily. Third-line immunosuppressive therapy is not well defined, tacrolimus should be taken in consider-
ations, and consultations with hepatologist can be helpful. Infliximab is not recommended for the treat-
ment of immune-related hepatitis.
Gastrointestinal (GI) irAEs are associated with a high incidence of treatment-related grade 3 or 4 
events with antiCTLA-4 antibody. GI irAEs that are commonly reported with anti-PD-1 treatment include 
colitis, diarrhea, and enteritis but just in 2-3% grade 3 or 4. The guidelines for managed GI irAe include 
close monitoring and prompt treatment of early symptoms. Non-inflammatory causes of symptoms, infec-
tion with different pathogens, should be ruled out. Colonoscopy and biopsy should be considered if the 
diagnosis is unclear or in the case of chronic grade 2 AEs. In the case of grade 3 or 4 AEs, systemic cortico-
steroids are required and corticosteroids also should be strongly considered if grade 2 AEs persist in spite 
of supportive care. Oral steroids starting at 1–2 mg/kg per day of prednisone can be used, but for patients 
requiring hospitalization or have significant comorbidities, intravenous methylprednisolone should be 
used for 1–2 days before an oral prednisone. If symptoms improve with steroid treatment, steroids should 
be continued until grade 1 or 0 toxicity is reached. In steroid-refractory cases, after 72 hours, the tumor 
necrosis factor-α (TNF-α) blocking agent infliximab (5 mg/kg once every 2 weeks) may be used. Treatment 
with infliximab can dramatically improve GI AEs, sometimes even within 24 hours, but this is not recom-
mended in patients with GI perforation or sepsis.
Pulmonary ir AEs, including pneumonitis was reported in up to 3% of the patients. A lung specialist 
consultation could be helpful and chest X-rays and CT scans of the thorax are necessary for diagnosis. 
Bronchoscopy and lung biopsy should be considered for patients with changes in respiratory status, 
including symptoms of upper respiratory infection, cough, shortness of breath, or decrease in pulse oxim-
etry below 90% on exertion. For patients with grade 2 mild-to-moderate symptoms or worsening of symp-
toms from baseline, treatment should be withhold and corticosteroids (1.0 mg/kg per day intravenous 
methylprednisolone) administered. If no improvement in symptoms observed after two weeks or if symp-
toms worsen, treatment for grade 3/4 severe events should be applied: discontinue treatment, hospitalize 
the patient with daily monitoring, and administer corticosteroids (2–4 mg/kg per day of intravenous meth-
ylprednisolone). If symptoms persist or worsen the use of non-corticosteroid immunosuppressive medica-
tion, such as infliximab should be considered.
Endocrine irAEs are generally of grade 1 and 2, but they can be difficult to diagnose. Incidence is 
approximately 6% for all grades, and 1% with grade 3/4. Nonspecific complaints, such as fatigue, nausea, 
amenorrhea, erectile dysfunction, hypotension, hyponatremia, hypoglycemia, and eosinophilia may 
reflect endocrine dysfunction. To identify endocrine dysfunction laboratory testing for thyroid-stimulat-
ing hormone, T4, adrenocorticotropic hormone (ACTH), cortisol and testosterone in males should be done. 
If hypophysitis is suspected (patient with a headache or visual symptoms) a magnetic resonance imaging 
(MRI) scan of the brain should be done, with pituitary cuts and visual field testing. Treatment with immune 
checkpoint inhibition may continue once appropriate hormone replacement initiated, and patients moni-
tored closely. If adrenal crisis is suspected based on severe dehydration, hypotension, stress-dose steroids 
should be administered, and delay or discontinuation of the treatment with anti-PD-1 therapy should be 
discussed.
The skin toxicities observed with anti-PD-1 agents include rash (14%), and pruritus (10%). Rash is 
typically focal with a maculopapular appearance occurring on the trunk, back, or extremities. All observed 
cases were low or moderate grade and successfully managed with topical steroids and anti-histamines for 
pruritus.
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Conclusion: Immunotherapy had improved the survival of metastatic melanoma patients. IrAEs can 
develop at any time, usually in first weeks until three months, but the first onset has been documented 
even one year after discontinuation of the treatment. Patients should be informed of the potential AEs of 
immunotherapy before treatment initiation. Dose reductions of PD-1 antibodies and/or ipilimumab have 
not been utilized in any trial and are not recommended after resolution of toxicity. For some cases a mem-
bers of the multidisciplinary team (endocrinologist, pulmonologist, gastroenterologist…) should be 
involved to address specific symptoms. In most cases, irAEs can be managed with treatment interruption 
and/or supportive care. If irAEs are not recognized early enough they can become severe and even life-
threatening. With timely and appropriate treatment, irAEs toxicities are usually reversible.
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Case report: Skin melanoma accounts for 4% of all dermatological malignancies, but it is responsible 
for about 80% mortality of skin tumors. Approximately 50 % of melanomas harbour activating point muta-
tions in the BRAF gene. Specific BRAF inhibitors, in combination with MEK inhibitors are the mainstays 
of treatment in patients with advanced locoregional inoperable and metastatic BRAF-mutant melanoma. 
A 69-year-old woman was presented with a stage IIIC cutaneous nodular melanoma on the lower left leg. 
Histological examination showed a 11 x 10 mm large lesion with tumor thickness of 4 mm, without ulcer-
ation (T4a), with large satellite nodules at 1mm distance from primary tumor and with present tumor 
infiltrating lymphocytes. Angiolymphatic invasion was described and a mitotic rate of 14/mm2 was 
detected. Resection margin was 2,5 mm. Sentinel lymph node biopsy was positive (N1a). Postoperative 
positron emission tomography (PET)/computerized tomography (CT) scan showed an uptake in two 
inguinal lymph nodes but no evidence of distant metastasis (cM0). After left inguinal lymphadenectomy, 
metastases were found in two of the five examined lymph nodes. BRAF testing showed positive mutation 
in BRAF gene. Multidisciplinary team decision was intensive clinical follow up. Regular every 3 months 
clinical visits with abdominal and inguinal ultrasound and dermatological exam were performed. In 
March 2017 clinical exam showed enlarged palpable inguinal lymph nodes, with few dark subcutaneous 
nodules around the operation scar. Cytological analysis of inguinal lymph node confirmed melanoma 
metastasis. Morphologic evaluation showed dissemination of disease in iliac, femoral, inguinal lymph 
nodes and in multiple left leg subcutaneous nodules. Patient started 1st line treatment with BRAF and 
MEK inhibitors, dabrafenib and trametinib in June 2017. At the beginning of treatment patient was ECOG 
0, laboratory tests were within normal ranges. Patient had no significant therapy toxicity. Ophthalmologi-
cal and cardiological examinations were regularly done. Clinical examination after 2 cycles showed sig-
nificant regression of subcutaneous lesions, and morphologic evaluation confirmed regression of disease. 
Further morphologic evaluation was performed every two cycles, with monthly clinical examination, and 
laboratory tests analysis. Stable disease persisted until February 2019, when metabolic and morphologic 
progression of one left inguinal lymph node occurred. Due to progression of disease, patient continued 
treatment with 2nd line therapy, immunotherapy with pembrolizumab. Continuous morphologic evalua-
tion and clinical follow up showed significant regression of disease. In September 2018, because of pain 
and superficial bleeding of subcutaneous metastasis, patient received palliative radiotherapy. Patient 
received 19 cycles of pembrolizumab, without significant toxicity and impact on quality of life. In April 
2019, patient developed symptomatic brain metastases. Palliative treatment was planned, but unfortu-
nately, due to fast clinical deterioration, patient died in October 2019, 31 months after diagnosis of meta-
static melanoma.
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While per se, stereotactic radiosurgery is not a new procedure, it has seen a new resurgence in recent 
years thanks to the advances in the technology and new understandings of the cancer.
While the first reports on stereotactic radiosurgery harken back to the mid-20th century and the con-
cept of gamma knife, it became more widespread by the use of modified accelerators and later with the 
purpose build accelerators, the procedure has long been restricted to the use in central nervous system. 
Introduction of stereotactic body frame has enabled the radiation oncologists to begin with the treatment 
of lesions elsewhere in the body, which were further facilitated by cyber knife and image guided radio-
therapy techniques. And while the intracranial lesions are still considered primary stereotactic targets, 
stereotactic body radiotherapy is used more and more often.
When started, most common indications for radiosurgery were brain metastases followed by arterio-
venous malformations. Typically they were solitary lesions, treated by single fraction radiosurgery. Shift 
from Lexell type frame and localizers to removable masks, has enabled us to start treating patients with 
lesions requiring multiple fractions, so radiosurgery has in some cases evolved to stereotactic radiother-
apy with up to 30 fractions, which by itself seems not to be an advance, but with the tighter margins, some 
benign diseases are being treated with far less side effects than previously. Simultaneously with the 
advances in central nervous system, stereotactic body radiotherapy started, it is now being used most 
widely in non-small cell lung cancer, liver tumours and spine, and new indications are emerging.
And as the basis for stereotaxy is polar coordinate system coupled with fixation and high precision 
delivery, things has changed somewhat. With the IGRT techniques, some authors claim that stereotactic 
radiotherapy is dead and prefer to use term high precision conformal radiotherapy, which in the case of 
central nervous system is practically synonymous, but is worth considering elsewhere, as the factors of 
inter and intra-fractional motions and changes are being introduced.
As to start with the endpoints, from the physical view, our aims are to optimise target dose and 
reduce normal tissue volumes and doses. We can achieve these endpoints by various means. Most com-
monly by using multiple small fields, we can also use multiple isocenters, multiple small beams, IMRT 
techniques, but also, we can start treating with hadron therapy. No method is superior to other in all 
aspects, while Cosi has shown that in case of treating skull base meningioma, Cyber knife was superior in 
shielding brain stemand the dose on optic nerve was higher. So every method has its proponents and 
adversaries but there is scarce evidence in favour of any method.
When considering stereotactic treatment, one should bear in mind, that although practical limitations 
for stereotactic treatment are quite lax, there are patients who don’t benefit from it. Thus, the number of 
indexes have been proposed for use in these patients, from the most simple recursive partitioning analysis 
index to more elaborate and specific graded prognostic assessment indexes, which provide some insight 
on who would benefit the most from the treatment.
In Slovenia, program of radiosurgery started in year 2000, when we performed first radiosurgery in 
patient with solitary brain metastasis of renal adenocarcinoma. Sixteen years on, the patient was still doing 
well. The method was performed on in-house modified accelerator with cone collimators and using TPS 
we have been using at the time. The method faded out for some years and we haven’t been treating 
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patients until 2006, when stereotactic radiosurgery programme commenced using Varian clinic 600 with 
micro-multi-leaf collimator and Brainscan/iPlan TPS. Since the start we treated up to 4 brain metastases on 
Saturdays, averaging 20 stereotactic radiosurgeries per year. In 2010, radiosurgery programme shifted to 
NovalisTx, we forgo use of frame in radiosurgery and nowadays patients are treated using stereotactic 
mask fixation, with the control of exactTrac using from 1 to 5 fractions. Stereotactic fractionated radio-
therapy is used for treatment of meningeal tumours and schwanomas. In 2015 we also started the pro-
gramme of stereotactic body radiotherapy, commencing with primary lung tumours and proceeding to 
liver, pancreas and spinal tumours. While all cranial stereotactic treatments are delivered on NovalisTx, 
extracranial treatments are also being performed on Elekta versa HD and Varian TrueBeam machine, 
which is now also being prepared for HyperArc treatment of brain lesions.
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CHEMOTHERAPY WITH PERIPHERAL BLOOD STEM-CELL 
TRANSPLANTATION
MARIJA GAMULIN1
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Germ Cell Tumors, Zagreb, Croatia
Testicular cancer (TC) is the most common cancer in young men with about one-third of all cases 
occurring in Europe. TC incidence rates increase in 21 out of 28 countries during the period 2010-2035. The 
TC incidence in 2010 and in 2035 in Croatia, age-standardized per 100 000 was 7.6 and would be 13.2. Cis-
platin is the key drug in the treatment of the TC and life expectancy is higher than in other solid tumors. 
Many patients with good risk metastatic seminoma are over-treated with the standard chemotherapy 
BEPx3 or PEx4. We use FDG-PET in seminoma patients to evaluate residual masses that are after chemo-
therapy >3cm in size. FDG PET performed within the correct timeframe of 4 to 12 weeks after chemo-
therapy is a standard diagnostic tool for clinical decision-making in seminoma patients with postchemo-
therapy residual masses.
Based on the efficacy of FDG-PET in seminoma, the authors of the SEMITEP (NCT01887340) study 
hypothesized that PET scans could be used to de-escalate therapy in good-risk seminoma. At a median of 
34 months of follow-up, there were no differences in PFS between patients who received four cycles of EP 
and those who received two cycles of EP + 1 cycle of carboplatin at AUC 7 and the latter was chosen for the 
de-escalation arm given in low-volume seminoma. The authors defined FDG-PET positivity by the pres-
ence of abnormal focal uptake. The primary study endpoint was the proportion of patients with negative 
early FDG-PET treated with de-escalating chemotherapy (CT). Secondary endpoints were PFS, OS, pro-
portion of patients with negative early FDG-PET and the inter-rater reliability of early FDG-PET. 72% of 
patients enrolled on SEMITEP had a negative early FDG-PET. De-escalating therapy based on this finding 
appears to be safe and feasible at least during three years of follow-up. While toxicities were essentially 
similar, there was a decreased amount of neuropathy in the de-escalation group. Longer follow-up and 
multicenter phase III will be required to understand if PET-based de-escalation of therapy has an impact 
on patient survival.    
20% to 30% of TC patients are either refractory or relapse following initial treatment and require sal-
vage CT. The most effective salvage CT regimen is controversial. Options include: 1. standard dose CT 
combining cisplatin and ifosfamide with either etoposide, vinblastine or paclitaxel or 2. high-dose chemo-
therapy (HDCT) with peripheral blood stem-cell transplantation. The most commonly used HDCT regi-
mens include either two or three courses of high dose carboplatin and etoposide followed by periferal 
blood stem cell transplantation. HDCT can achieve better results, 63%, with 2-year PFS when given as the 
second line, and 49% as the third line therapy or later. There is ongoing international randomized multi-
center phase III the “TIGER“ trial comparing conventional-dose chemotherapy with TIPx4 vs TI-CE (pacli-
57
Lib Oncol. 2020;48(Suppl 1):3–69
taxel, ifosfamide 2x) followed by HDCT with carboplatin and etoposide x3 as the first salvage treatment in 
relapsed or refractory germ cell tumors. This study will elucidate the usage of HDCT in regard to the TC 
risk group.
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Androgen deprivation therapy of prostate cancer has been a cornerstone of disease treatment. The 
story began with Charles Brenton Huggins who established a method to measure the effect hormone 
changes have on prostatic function. He found out that castration or estrogen administration led to glandu-
lar atrophy. In 1941 the beneficial effect of androgen ablation on metastatic prostate cancer was realised 
when Huggins and Clarence Hodges treated patients by either castration or estrogen therapy. Huggins 
was the first to use a systemic approach to treat prostate cancer. Huggins was awarded the Nobel Prize in 
Physiology or Medicine in 1966. Nowadays story has somewhat changed meaning that androgen depriva-
tion therapy (ADT) still is a method of choice but has to be combined with other therapy modalities such 
as radiotherapy, chemotherapy or novel hormonal agents. ADT alone is no longer a valid, evidence based, 
therapeutic approach except in isolated cases in which due to comorbidities or other medical conditions 
there is no possibility of combining other treatment methods. When ADT is combined with radiotherapy 
in patients with high risk prostate cancer a question of therapy duration has been raised. Previous praxis 
suggested that duration of the treatment should be 36 months. Nabid and colagues have conducted a 
clinical trial evaluating a duration of ADT combined with radiotherapy in high risk prostate cancer patients 
and concluded that 18 months of ADT is not inferior to 36 months of ADT. Also 18 months of ADT con-
comitant with radiotherapy may in selected patients improve quality of life without compromising overall 
survival. This kind of treatment is an attractive alternative for patients not tolerating well ADT. With the 
emergence of recent trials, the treatment for hormone-sensitive metastatic prostate cancer (hsMPC) is 
changing from ADT alone to combination therapy – chemotherapy or novel androgen receptor blocking 
agents. Both, docetaxel chemotherapy and abiraterone in addition to ADT have been studied and had 
shown to improve outcomes. The Systemic Therapy in Advanced and Metastatic Prostate Cancer Evalua-
tion of Drug Efficacy (STAMPEDE) and Chemo Hormonal Therapy versus Androgen Ablation Random-
ized Trial in Extensive Disease (CHAARTED) trials established docetaxel chemotherapy, in addition to the 
ADT, as the first-line therapy in metastatic prostate cancer. In the CHAARTED and the STAMPEDE (Arm 
C) trials, the hazard ratio (HR) for OS on adding six cycles of docetaxel to ADT was 0.61 and 0.78. Clinical 
studies LATITUDE and STAMPEDE trials (Arm G) have explored the role of abiraterone in combination 
with prednisolone in addition to ADT in newly diagnosed high-risk hsMPC cancer patients. The LATI-
TUDE study included 1,199 patients who were randomized to receive either ADT plus abiraterone (1000 
mg daily) plus prednisone (5 mg daily) (treatment arm – 597 patients) or ADT plus dual placebos (control 
arm – 602 patients).The study found that the treatment arm had an improvement in both the overall sur-
vival (OS - HR = 0.62; 95% CI = 0.51–0.76, P < 0.0001) and progression free survival (PFS - HR = 0.47; 95% 
CI = 0.39–0.55, P < 0.0001). The STAMPEDE (arm G) trial with very similar design as LATITUDE involved 
a total of 1,917 patients and showed an improvement of 37% in the OS (HR = 0.63; 95% CI = 0.52–0.76, P < 
0.001). Another issue has been raised in disease defined as non-metastatic castration resistant prostate 
cancer (nmCRPC). This is a state in which a high velocity (PSA doubling time ≤ 10 months) PSA rise is 
noted in spite of castration level testosterone in serume and no metastatic disease with conventional imag-
ing methods (CT scan, bone scintigraphy). This is a very serious and deadly disease which had no thera-
peutic options till recent. There are three possible clinical scenarios in the development of such disease. 
First is PSA rising during radiotherapy with ADT, second is salvage ADT after local treatment (surgery 
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and/or radiotherapy) and third PSA rise after ADT alone for localized disease (option which should not be 
done any more). Three clinical trials examined apalutamide (SPARTAN), enzalutamide (PROSPER) and 
darolutamide (ARAMIS) in high-risk M0 CRPC. All trials had similar design with 1200-1500 patients 
enrolled comparing active drug to placebo. Primary endpoint was defined as metastasis free survival and 
secondary endpoints were overall survival (OS), time to first sceletal related event, time to application of 
first chemotherapy and time to pain progression. All three clinical trials have met their primary endpoints 
showing metastasis free survival in the range of 36-40 months, and the results for overall survival are not 
yet available even though some interim analysis in ARAMIS trial show promising results. All this novel-
ties in hormonal therapy of different stages of prostate cancer gives us hope to improve the number of 
completely cured prostate cancer patients. For those patients who cannot be completely cured, this new 
kind of treatment approach allows to have a significantly better life quality and a significant delay of 
metastatic disease spread and development and very probably possibility of having a longer time of over-
all survival.
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TREATMENT
MILENA GNJIDIĆ1
1 University Hospital Centre Zagreb, Department of Oncology, Zagreb, Croatia
Prostate cancer (PC) is one of the most common cancers in Western World and is second leading cause 
of cancer deaths in men behind lung cancer. Metastatic prostate cancer is an incurable disease with different 
behavior. The mainstay of systemic prostate cancer treatment is hormonal manipulation - chemical or surgi-
cal castration. But since 2014 addition of chemotherapy or new hormone agents to castration has prolonged 
survival in castration-sensitive prostate cancer (CSPC). Docetaxel is the only non-hormonal agent used in 
CSPC treatment with androgen deprivation therapy (ADT). Despite great advances in CSPC treatment many 
questions remained unresolved like drug and patient selection, optimum sequencing or combining, duration 
of therapy. Some data from the last ASCO-GU showed that gene expression profiling could help classify 
prostate cancer as luminal A, luminal B and basal subtype and predict benefit of adding docetaxel to ADT in 
luminal B subtype. In castration-resistant prostate cancer (CRPC) the treatment landscape is evolving, with 
new agents and strategies, and more optimal use of existing therapies under constant development. The 
main non-hormonal agent in CRPC is cabazitaxel and showed benefit in patients who had been previously 
treated with docetaxel and abiraterone or enzalutamide (CARD study). New data indicated importance of 
drug sequencing and support the use of earlier chemotherapy in the castration resistant state. The great 
efforts are still needed to properly select the most appropriate treatment for each single patient. Many prog-
nostic and predictive biomarkers have been studied, none of which has an established validated role in daily 
clinical practice. However, better understanding of PC biology, a broader application of metastatic biopsies 
and liquid biopsy and molecular testing will help to achieve better treatment outcome. Recently, we have 
learned that approximately 12% of patients with mCRPC have germline DNA-repair pathway mutations, 
and 20-25% have somatic mutations and those patients could benefit form poly ADP-ribose polymerase 
(PARP) inhibitors or platinum chemotherapy. Based on early evidence from PARP-inhibitors studies, it 
seems that men with prostate cancers harboring mutations in BRCA1/2 will have the greatest response rates 
to PARP inhibitors. Whether or not men with other mutations in DNA-repair genes will have response 
remains to be seen. New data also showed that approximately 3-5% prostate cancers harbor mutations in 
mismatch-repair (MMR) genes and may benefit from pembrolizumab, FDA approved agent for all cancers 
with MMR deficiency or microsatelite instability (MSI)-high status. That is why some guidelines recommend 
germline and somatic genetic testing for all men with metastatic PC or mCRPC. Another emerging therapies 
in mCRPC are directed towards the prostate-specific membrane antigen (PSMA) as radionuclid therapy with 
beta-emitter lutetium-177 and chimeric antigen receptor (CAR) T-cells therapy with PSMA as target. We are 
eagerly awaiting results from many ongoing clinical trials about PARP-inhibitors, immunotherapy and 
many other new agents and various combinations in genomically-selected PC patients.
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The importance of clinical trials can be assessed by their impact on clinical guidelines for the treat-
ment. In the recent period, the results of published radiotherapy studies are important for improving 
techniques and better defining radiation indications in the treatment of patients with prostate cancer.
In 2018, STAMPEDE A1 and HORRAD clinical trials were published to demonstrate the beneficial 
effect of prostate radiotherapy in primary metastatic prostate cancer. In the STAMPEDE A1 trial, the risk 
of death of locally irradiated patients with low-volume disease was reduced by 32%. In 2019, STOPCAP 
systematic review and meta-analysis of both studies showed significantly better biochemical disease con-
trol and survival without biochemical, clinical or radiographic progression in irradiated patients with 
primary metastatic prostate cancer. The greatest benefit was seen in patients with less than 5 bone metas-
tases. Subsequent analysis of the STAMPEDE A1 trial showed a significant 38% reduction in mortality and 
a 43% reduction in the risk of disease recurrence in irradiated patients with less than 4 bone metastases. In 
2019, prostate cancer radiotherapy in addition to androgen deprivation in patients with primary meta-
static low-volume disease is recommended according to EAU guidelines.
It is important to highlight newly published clinical trials that tested radiation after prostatectomy. 
The results of the RADICALS-RT and RAVES studies were announced on the ESMO 2019 and ASTRO 
2019 congresses. A prospective RADICALS-RT study included 1396 patients with adverse prognostic fac-
tors after radical prostatectomy. There was no significant difference in survival without biochemical pro-
gression between patients who received immediate adjuvant radiotherapy and patients who received 
early salvage radiotherapy. However, more adverse events have been reported with adjuvant radiother-
apy. Over 60% of patients in the salvage group did not need further radiation. The smaller RAVES trial 
confirms the equal effectiveness of adjuvant and salvage radiotherapy in biochemical disease control. The 
ARTISTIC meta-analysis included both of these studies and the GETUG-AFU17 trial and confirmed the 
equal value of radiation immediately after prostatectomy (adjuvant radiotherapy) and delayed radiation 
(salvage radiotherapy) in the postoperative treatment of prostate cancer patients.
In the recent period we are faced with the widespread acceptance of ultra-hypofractionated radio-
therapy (≥5 Gy) in primary treatment for prostate cancer. Systematic review of over 6000 patients treated 
by stereotactic body radiation therapy (SART or SBRT) showed a 7-year biochemical control of the disease 
in 93.7% of patients with adverse complications of grade ≥3 in only 3.1%. In 2019, the first results of two 
prospective randomized studies were published. The HYPO-RT-PC trial included 1200 patients, mainly 
intermediate-risk. SBRT was not inferior to conventional treatment in progression-free survival. Slightly 
more acute side effects were reported. The PACE-B trial included 874 patients and showed no difference 
in acute adverse events between ultra-hypofractionated radiotherapy and other radiation regimens. In 
2019, the common guidelines of ASTRO, ASCO and AUA included SBRT into standard local treatment in 
low-risk patients, and, as a therapeutic option, in intermediate-risk patients with recommended additional 
systematic monitoring.
Published studies are changing or will soon change the way how radiotherapy is used in prostate 
cancer patients. Prostate radiotherapy is becoming a mandatory part of the treatment of primary meta-
static low-volume disease. Adjuvant radiotherapy will be replaced by early salvage radiotherapy. Radio-
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therapy in patients with local disease and low- and, partly, intermediate-risk will be ultra-hypofraction-
ated and performed by stereotactic technique.
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Bladder cancer is the tenth most common cancer worldwide, and it is about four times more common 
in male. Major histopathological type is urothelial cancer, caused predominantly by smoking, while in 
northern Africa due to other causal agent (infection with parazite Shistosoma) squamous cell cancer com-
prises approximately 75% of the cases. Vast majority of urothelial cancers arise in the bladder, then in renal 
pelvis and ureter. In 75% of cases it is diagnosed as non-muscle-invasive disease, meaning papillary non- 
invasive tumor (Ta), or only lamina propria invasive tumors (T1) or flat high-grade lesions (CIS), and in 
rest of the patients as a muscle-invasive disease and metastatic cancer.
In narrow sense neoadjuvant treatment is term reserved for chemotherapy applied in muscle- inva-
sive localised bladder cancer before locoregional treatment, typically radical cystectomy. Although neoad-
juvant chemotherapy has been proven to prolong overall survival, and it is recommended by various 
guidelines of oncological and urological societies, it is still largely underutilised. The main obstacle is 
probably lack of real multidisciplinary approach to these patients leading to assumptions that they are 
frail and not a good candidates for chemotherapy, and that this approach would lead to delay of curative 
intent surgery. As we now that only 50% of patients are alive 5 years after radical cystectomy it is clear that 
multimodal approach involving potent systemic therapy in order to decrease rate of distant metastases 
and prolong survival is needed. Recommended neoadjuvant chemotherapy protocols are cisplatin-gem-
citabine (CG) combination and dose dense (dd) MVAC protocol (methotrexate, vinblastine, doxorubicin 
and cisplatin). There is a recent report on higher pathological complete response rate on dd MVAC in 
comparison with CG. Preliminary report of GETUG/AFU V05 VESPER randomized trial comparing these 
two protocols confirmed better pathological response od dd MVAC with higher acute toxicity. We are 
expecting outcomes of survival analysis in 2021.
Novel neoadjuvant therapy approaches are combining immunotherapy with chemotherapy or 
exploring immunotherapy alone (PURE-01, ABACUS, BLASST-1 trials). Major efforts are being made to 
find a predictive biomarker for response on neoadjuvant chemotherapy. The largest research is done in 
molecular profiling of urothelial cancer. By different assays several specific molecular subtypes of muscle-
invasive bladder cancer have been identified. Investigations, that should be prospectively validated, sug-
gest that basal and luminal tumors have equivalent response to neoadjuvant chemotherapy and that basal 
tumors may benefit the most from neoadjuvant chemotherapy.
The level of evidence for adjuvant chemotherapy is less strong, but it should be considered based on 
pathological findings on radical cystectomy, if neoadjuvant therapy has not been applied. Phase III 
IMvigor-010 clinical trial testing adjuvant atezolizumab versus observation after radical cystectomy failed 
to meet primary endpoint of disease-free survival for muscle-invasive urothelial cancer.
Adjuvant intravesical therapy with Bacillus Calmette Guerin (BCG) or chemotherapy is used to 
reduce recurrences or delay disease progression to higher stages or grades. Unfortunately, due to global 
shortage of BCG, alternative agents and therapies are urgently needed. In 2018. American Food and Drug 
Association (FDA) has approved pembrolizumab, anti PD-1 antibody for treatment of high risk BCG-
unresponsive non-muscle-invasive bladder cancer with CIS.
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In conclusion, bladder cancer has high global incidence and especially prevalence of patients with 
early stages of the disease. Goal is to treat carefully and vigorously non-muscle- invasive cancer to prevent 
its’ invasion and further progression of the disease. Muscle-invasive bladder cancer is highly aggressive 
disease with only 50% survival on five years with radical cystectomy which prompts use of neoadjuvant, 
and sometimes adjuvant chemotherapy according to the best available evidence. We are still lacking 
proven predictive biomarkers for right patient selection for this approach. There are new agents and 
modalities on horison, primarily immunotherapy that has, after proven benefit in metastatic setting, shown 
good results in early stages of the disease and is being tested in number of randomised clinical trials.
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There has been tremendous progress observed in metastatic setting of urothelial cancer, after many 
decades of stagnation. In last several years five immune check-point inhibitors have been approved for 
treatment of advanced or metastatic urothelial cancer after failure of prior platinum-based chemotherapy: 
atezolizumab, nivolumab, pembrolizumab, avelumab and durvalumab. In the first line setting, pembroli-
zumab and atezolizumab are approved for cisplatin-ineligible patients, however their use is restricted 
only to programmed death-ligand 1 (PD-L1) expressing tumors.
Role of anti-PD-1/PD-L1 antibodies in the first line treatment of metastatic disease will be defined by 
following ongoing large phase III trials: IMVigor130 (atezolizumab vs platinum-based chemotherapy + 
atezolizumab vs cisplatin + gemcitabine or carboplatin + gemcitabine), DANUBE (durvalumab vs dur-
valumab + tremelimumab vs cisplatin + gemcitabine or carboplatin + gemcitabine), KEYNOTE361 (pem-
brolizumab + cisplatin/gemcitabine or pembrolizumab + carboplatin/gemcitabine vs pembrolizumab vs 
cisplatin + gemcitabine or carboplatin + gemcitabine), CheckMate901 (nivolumab + ipilimumab vs nivo-
lumab + cisplatin/gemcitabine vs cisplatin + gemcitabine or carboplatin + gemcitabine), and finally JAVE-
LIN Bladder 100 (first line chemotherapy + avelumab switch maintenance vs observation). So far, interim 
PFS and OS analysis of IMVigor130 trial was reported on ESMO 2019. Atezolizumab combined with plat-
inum-based chemotherapy showed PFS benefit and trend towards OS benefit, compared to chemotherapy 
arm. Importantly to note, atezolizumab alone arm fared not better than chemotherapy arm. Use of cispla-
tin was associated with improved OS in combinational arm.
Javelin Bladder 100 trial recently (January 6, 2020) reported that trial met it’s OS endpoint in the 
planned interim analysis, meaning that avelumab given as switch maintenance after standard cisplatin/
gemcitabine chemotherapy significantly prolonged OS compared to observation.
Very recently, we witnessed another breakthrough in bladder cancer treatment. Concept of antibody-
drug conjugates proved to be efficient in metastatic bladder cancer. Enfortumab Vendotin (EV) represents 
the first in class antibody-drug conjugate which specifically targets Nectin-4, transmembrane cell adhesion 
molecule highly expressed in urothelial cancer cells. EV-201 phase II study included 125 patients who 
failed prior platinum containing and immune checkpoint inhibitor therapy. Overall response rate was 
44%, including 12% complete responses and 32% partial responses. Median duration of response was 7.6 
months with manageable toxicity. Based on these results, on December 18, 2019, the Food and Drug 
Administration granted accelerated approval to enfortumab vedotin for patients with locally advanced or 
metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-
containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
Next step in further development is testing EV in combination with immunotherapy (pembroli-
zumab).
At the 2020 ASCO GU meeting updated data were presented on a cohort of cisplatin-ineligible patients 
receiving first line enfortumab vedotin + pembrolizumab (EV-103 trial). The study included 45 patients. 
After a median follow-up period of 11.5 months, the confirmed investigator-assessed objective response 
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rate (ORR) was 73.3% (95% CI [58.1, 85.4]). A total of 15.6% of patients had a complete response, and the 
disease control rate was 93.3%. The responses appeared durable, with 55% ongoing at the time of data 
cutoff; 11 responses lasted beyond 10 months, and the median duration of response was not yet reached. 
The most common treatment-emergent adverse events associated with the regimen included fatigue (58%; 
11% grade 3 or higher), alopecia (53%), and peripheral sensory neuropathy (53%; 4% grade 3 or higher).
Next antibody-drug conjugate showing activity in bladder cancer is Sacituzumab Govitecan (SG), a 
Trop-2 directed antibody-drug conjugate linked to SN-38, a toxic payload that is the active metabolite of 
the chemotherapy drug irinotecan. TROPHY-U-01 trial was a phase 2 open-label study of SG on 100 
patients with metastatic urothelial cancer who progressed on platinum-based chemotherapy or an immune 
checkpoint inhibitor therapy. Last updated data was presented at ESMO 2019. After a median follow-up 
of 4.1 months, 57% of patients continued on treatment. The ORR was 29% (10/35) with 6% of patients (2/35) 
achieving a complete response. Of the 10 patients who responded, 8 had ongoing response at the time of 
data collection. 74% of patients demonstrated a reduction in tumor burden by RECIST criteria. These data 
demonstrate that Sacituzumab Govitecan is a promising novel antibody-drug conjugate in the third-line 
setting following platinum-based chemotherapy and an immune checkpoint inhibitor therapy.
Next recently established breakthrough therapy for locally advanced or metastatic urothelial cancer 
is erdafitinib, a tyrosine kinase inhibitor of fibroblast growth factor receptor (FGFR1–4). Alterations in 
FGFR genes are common in urothelial carcinoma and may be associated with lower sensitivity to immune 
interventions. In phase 2 study, 99 patients with locally advanced and unresectable or metastatic urothelial 
carcinoma with prespecified FGFR alterations, who progressed during or after at least one course of che-
motherapy or within 12 months after neoadjuvant or adjuvant chemotherapy received erdafitinib in either 
an intermittent or a continuous regimen. Overall response rate was 40% (3% with a complete response and 
37% with a partial response). Among the 22 patients who had undergone previous immunotherapy, the 
confirmed response rate was 59%. The median duration of progression-free survival was 5.5 months, and 
the median duration of overall survival was 13.8 months.
Next step in drug development is combination FGFR pathway inhibitors with immune checkpoint 
inhibitors, the concept currently tested in ongoing phase I FORT-2 trial in patients with mRNA positive 
FGFR1/3 mutant metastatic urothelial cancer (rogaratanib+atezolizumab vs atezolizumab alone).
In conclusion, in last few years, a significant progress has been made in treatment of patients with 
metastatic bladder cancer, with advent of immune check-point inhibitors, targeted therapy, and antibody-
drug conjugates. Combinational therapies are of special interest as they offer unique opportunity for dis-
ease control. Ongoing trials will define optimal regimen of systemic treatment.
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Kidney cancer treatment options continue to evolve and develop at rapid pace. Recently, on ASCO 
GU 2020 meeting, several important updates of key trials were presented. The final analysis of Check-
Mate 025 study, which established nivolumab as a standard 2nd-line therapy in patients that progressed 
on vascular endothelial grow factor (VEGF) targeted therapy was presented with over 5 years of follow-
up. Final trail results showed that with long-term follow-up, nivolumab was associated with improved 
OS, with a median OS of 25.8 months versus 19 months, HR 0.73, p<0.0001, when compared to everolimus. 
Progression-free survival was also improved with nivolumab (4.2 months versus 4.5 months, HR 0.84, 
p=0.03). An overall response rate of 23% was observed with nivolumab, compared to 17% with everolimus 
(p<0.0001) and nivolumab was also associated with prolonged duration of response (18.2 months). 
Nivolumab toxicity profile was similar to prior reports with no new signals of additional toxicity. Com-
mon adverse events with nivolumab included fatigue, diarrhea, pruritis and decreased appetite. Overall 
these data confirm the efficacy and safety of nivolumab in this setting as standard second line treatment.
Second important trial that was presented was a phase I/II study of sitravatinib combined with 
nivolumab in patients with advanced clear cell renal cancer that progressed on prior anti-angiogenic 
therapy  In patient who have been previously treated with a VEGF tyrosine kinase inhibitor (TKI), the 
checkpoint inhibitor nivolumab represents a standard 2nd-line strategy.
Sitravatinib is an orally-available small molecule, multi-targeted TKI. The hypothesis of this study 
was that sitravatinib could augment nivolumab responses. Nivolumab plus sitravatinib showed promis-
ing efficacy, with 15/38 (39%) achieving a confirmed objective response and 35/38 (92%) achieving clinical 
benefit (stable disease or partial response or completed response). At a median follow-up of 17.7 months, 
median overall survival had not been reached with 79% of patients alive. Median duration of treatment 
(10.3m) compared favorably to historical report of nivolumab alone (4.6 months). This early phase phase 
trial of sitravatinib, a multi-targeted oral TKI, in combination with nivolumab in pre-treated advanced 
clear-cell kidney cancer showed higher objective response rate and longer PFS than historically reported 
single-agent nivolumab in this setting.
Also, CheckMate-214 trial was updated on ASCO GU 2020 meeting, now with minimum follow-up 
of 42 months. The overall survival benefit for combination nivolumab/ipilimumab was maintained at a 
42-month minimum follow-up (HR 0.66, 95% CI 0.55-0.90, P<0.0001). The median overall survival for com-
bination nivolumab/ipilimumab was 47 months versus 26.6 months in the sunitinib group. This overall 
survival benefit also held true in the secondary endpoint of intention to treat analysis, though with a 
slightly higher hazard ratio (HR 0.72, 95% CI 0.61-0.86, P = 0.0002. The exploratory analysis of the efficacy 
of combination nivolumab/ipilimumab in favorable-risk patients compared to sunitinib showed no overall 
survival benefit (HR 1.19, 95% CI 0.77-1.85, P = 0.44). As expected for good risk patients, the median over-
all survival was not reached in either group. Confirmed response rates were higher with combined immune 
checkpoint blockade relative to sunitinib in the intermediate/poor risk group, but not in the good risk 
group. The median duration response of combined checkpoint blockade has not been reached. Consistent 
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with the complete response data, there was a plateau in the PFS nivo/ipi curve at 34%. In post-hoc analysis, 
overall survival probability in patients who discontinued therapy appears similar to the patients who con-
tinued on therapy in the intention to treat analysis. In summary, at 42 months of minimum follow-up 
(median 49 months), the overall survival and objective response rate seen with combined nivolumab 
and ipilimumab persisted as superior to sunitinib for intermediate/poor risk patients with metastatic 
renal cell cancer  A post hoc analysis suggests that the overall survival benefit may persist in patients 
despite having to discontinue therapy due to adverse side effects. No specific benefit for this combination 
relative to TKI therapy was seen in the good risk population, though longer follow-up will be helpful for 
confirming this.
Recently updated ESMO guidelines now as first line treatment recommend pembrolizumab/axitinib 
combination as standard in good risk patients. Alternative options include sunitinib and pazopanib. In 
intermediate-risk and poor-risk patients two recommended regimens are pembrolizumab/axitinib and 
nivolumab/ipilimumab while alternatives include sunitinib, pazopanib and cabozantinib.
Currently, there is important work in progress related to biomarkers which could predict better 
response to immune checkpoint inhibitors as compared to VEGF-tarteded antiangiogenesis TKIs. Poten-
tially, TKI could work better in tumors where the oncogenic driver is angiogenesis axis, while immune 
checkpoint inhibitors could work better in tumors with present immunosupressive signature. Updates 
from Immotion151 trial (atezolizumab/bevacizumab versus sunitinib) biomarker analysis are expected in 
later 2020 (molecular gene expression signatures were correlated with clinical outcomes, prognostic risk 
groups, and tumor histology).
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The case aims to acknowledge long lasting benefit of different tyrosine kinase inhibitors (TKI) given 
in sequence and emphasizes the absence of cross-resistance and the need for continuous effective antitu-
mor treatment after failure of immune checkpoint blockade.
The 58-year old patient was first referred to urology department in September 2005 due to accidental 
ultrasound confirmed mass in the right kidney. Initial staging showed no evidence of distal metastasis. 
Radical right nephrectomy was performed and pathology report confirmed clear cell renal carcinoma. He 
was followed until April 2008 when CT scan showed multiple, bilateral lung metastasis. He started treat-
ment with sunitinib 50 mg 4/weeks schedule, later reduced to 37,5 mg due to the side effects. Control 
radiological assessment confirmed partial response but in March 2015 after nearly 7 years of sunitinib 
treatment there was radiological progression in the lungs and dose was due to be increased to 50 mg 2/
weeks schedule. However, the treatment was not started because patient developed acute myocardial 
infarction and later when he recovered was operated because of cholangitis. After 6 months with no treat-
ment he was retreated with sunitinib 50 mg and on the first evaluation there was 50% diameter regression 
of the lung metastasis and new soft tissue metastasis in the right shoulder but unfortunately sunitinib was 
discontinued due to cardiac toxicity. Patient was discussed on the multidisciplinary tumor board and 
started treatment with nivolumab 3mg/kg intravenously every 2 wk. After 3 months of treatment there 
was significant clinical progression in the lungs and new large painful bone metastasis in the right knee. 
The treatment with nivolumab was stopped, patient was discussed on the multidisciplinary tumor board 
and due to favorable toxicity profile treatment with pazopanib was recommended. In October 2016 he 
started with reduced dose of pazopanib 400 mg and 600 mg per day alternately and since there was no 
significant cardiac toxicity the dose was increased to 600 mg per day. At the first evaluation 3 months later 
there was significant reduction of the all sites of metastatic disease and he continued his treatment until 
August 2019 when there was radiologically confirmed progression in the lungs, shoulder and new large 
lytic lesion in the iliac bone. The bone metastasis was irradiated and in November 2019 a fourth line of 
systemic treatment was started with cabozantinib in reduced dose of 40 mg. The treatment is well toler-
ated and the first evaluation after 3 months showed radiological regression of all metastasis.
In the conclusion this case shows that renal cell carcinoma is heterogeneous disease with proportion 
of patients needing long-lasting and continuous treatment with TKI both before and after treatment with 
immunotherapy.
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